

**Practical Access to Axially Chiral Sulfonamides and Biaryl
Amino Phenols *via* Organocatalytic Atroposelective *N*-Alkylation**

Lu et al.

Supplementary Methods

General information. ^1H and ^{13}C NMR spectra were recorded on a Bruker AMX500 (500 MHz) spectrometer. Chemical shifts were reported in parts per million (ppm), and the residual solvent peak was used as an internal reference: ^1H (chloroform δ 7.26; DMSO δ 2.50; acetone- d_6 δ 2.05), ^{13}C (chloroform δ 77.0; DMSO δ 39.5; acetone- d_6 δ 205.87, 30.60). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad), coupling constants (Hz) and integration. Melting point (**MP**) was obtained on Buchi B-540. For thin layer chromatography (**TLC**), Merck pre-coated TLC plates (Merck 60 F254) were used, and compounds were visualized with a UV light at 254nm. High resolution mass spectra (**HRMS**) were obtained on a Finnigan/MAT 95XL-T spectrometer. **Optical rotations** were recorded on an mrc AP81 automatic polarimeter. Enantiomeric excesses (**ee**) were determined by HPLC analysis on Agilent HPLC units, including the following instruments: pump, LC-20AD; detector, SPD-20A; column, Chiralcel OD-H, Chiralpak AD-H, AS-H, ID or IE.

All commercially available reagents listed below were used as received for the reactions without any purification. 3,5-dimethylaniline, 2-naphthol, 3-Bromo-2-naphthol, 6-Bromo-2-naphthol, 7-Bromo-2-naphthol, 7-Methoxy-2-naphthol, 6-Hydroxy-2-naphthoic acid, 9-Phenanthrol, 3,5-Dibromophenol and 4-Bromo-3,5-dimethylphenol were purchased from Sigma aldrich. Liquid reagents were handled with a micropipette. THF was dried on alumina columns using a solvent dispensing system.

For the kinetic resolution, selectivity factors (S) were calculated according to Kagan's equation: $S = \ln((1-c)(1-ee_{\text{rsm}}))/\ln((1-c)(1+ee_{\text{rsm}}))$, wherein c is conversion of the reaction, ee_{rsm} is the enantiomeric excess of the recovered starting material. Conversions (Conv.) were calculated by ^1H NMR.


The MBH cabonate **2a** and **2b** were synthesized in one step from commercially available materials by literature methods.^[1]

Substrates syntheses:


Synthesis of 1a-1k:

These substrates were synthesized following our previous method.^[2]

Synthesis of 1l:




Our previous one-pot method was followed to yield this intermediate in 52% yield as a brown solid.^[3]
MP: 155 - 156 °C. **¹H NMR** (400 MHz, CDCl₃): δ 7.93 – 7.84 (m, 2H), 7.56 (dd, *J* = 8.9, 2.3 Hz, 1H), 7.42 – 7.32 (m, 4H), 6.45 (dd, *J* = 8.9, 2.4 Hz, 1H), 5.25 (s, 1H), 3.98 (s, 2H), 3.67 (s, 3H). **¹³C NMR** (100MHz, CDCl₃): δ 158.37 , 151.46 , 144.25 , 133.40 , 132.57 , 130.40 , 129.37 , 128.33 , 126.90 , 124.11 , 123.60 , 117.78 , 112.92 , 106.77 , 102.25 , 101.38 , 55.98. **HRMS (ESI)** *m/z* Calcd for [C₁₇H₁₄BrNNaO₂, M + Na]⁺: 366.0100; Found: 366.0104.



A solution of amino alcohol (1 mmol) in anhydrous THF (5 mL) was cooled to -78 °C. *n*-Butyllithium (6 mmol, 2 M in cyclohexane) was added slowly to the reaction flask and stirred for 1 h at -78 °C. The reaction mixture was then left to stir at room temperature overnight. Reaction quenched with NH₄Cl and extracted with ethyl acetate. Combined organic layers washed with brine and dried with Na₂SO₄ and evaporated *in vacuo*. Crude residue was purified by column chromatography (81% yield). Off-white solid. **MP:** 180 - 181 °C. **¹H NMR** (400 MHz, CDCl₃): δ 7.77 – 7.67 (m, 2H), 7.28 – 7.14 (m, 5H), 6.42 – 6.38 (m, 2H), 5.27 (s, 1H), 3.54 (s, 3H), 3.39 (s, 2H). **¹³C NMR** (101 MHz, CDCl₃) δ 159.16 , 151.49 , 146.96 , 132.95 , 130.65 , 129.94 , 129.34 , 128.25 , 126.61 , 124.42 , 123.39 , 117.76 , 113.32 , 108.73 , 106.15 , 101.26 , 55.77 . **HRMS (ESI)** *m/z* Calcd for [C₁₇H₁₆NO₂, M + H]⁺: 266.1176; Found 266.1167.

A solution of amino alcohol (0.6 mmol) in anhydrous CH₂Cl₂ (15 mL) was cooled to 0 °C. Pyridine (0.9 mmol) and MsCl (0.6 mmol) were added successively to the reaction flask. The reaction mixture was then left to stir at room temperature overnight. The solvent was evaporated *in vacuo*. Crude residue was purified by column chromatography (62% yield). White solid. **MP:** 214 - 215 °C. **¹H NMR** (400 MHz, Acetone-*d*₆): δ 8.52 (br, 1H), 7.91 – 7.86 (m, 2H), 7.49 (t, *J* = 8.2 Hz, 1H), 7.42 (dd, *J* = 8.3, 1.1 Hz, 1H), 7.40 – 7.30 (m, 3H), 7.21 (ddd, *J* = 7.4, 2.2, 0.9 Hz, 1H), 7.01 (dd, *J* = 8.2, 1.2 Hz, 1H), 6.61 (br, 1H), 3.65 (s, 3H), 2.79 (s, 3H). **¹³C NMR** (100MHz, Acetone-*d*₆): δ 158.77 , 152.72 , 137.80 , 133.81 , 130.31 , 129.79 , 129.07 , 128.23 , 126.70 , 123.81 , 123.19 , 118.47 , 115.69 , 112.46 , 112.29 , 107.51 , 55.22 , 38.88 . **HRMS (ESI)** *m/z* Calcd for [C₁₈H₁₆NO₄S, M - H]⁻: 342.0806; Found: 342.0808.


Synthesis of 1m-1o:



The NOBIN analogs were synthesized by the known procedures.^[4,5]

A solution of NOBIN analog (0.6 mmol) in Pyridine (1mL), TsCl (0.6 mmol) were added to the reaction flask. The reaction mixture was then left to stir at room temperature overnight. The solvent was evaporated *in vacuo*. Crude residue was purified by column chromatography.


Synthesis of 1p:



The first step followed our previous procedure to deliver the free amino phenol intermediate.^[2]


To a solution of the amino phenol (1 mmol) in THF at -78 °C was added a solution of NaHMDS (3.3 equiv) in THF (5 mL) via syringe. The reaction mixture was warmed to room temperature and stirred for 30 minutes. The reaction was then recooled to -78 °C and a solution of (Boc)₂O (1 equiv) in THF (5 mL) was added dropwise to the reaction mixture. The reaction was allowed to stir at -78 °C for 2 hours, then gradually warm to room temperature. The reaction was then heated to 65 °C and allowed to stir overnight. The reaction was quenched by the addition of 20 mL of water and 2 M HCl was added gradually till pH = 3. The reaction mixture was extracted with ethyl acetate (3 X 15 mL), the combined organic phase was washed with brine, dried over Na₂SO₄, filtered and concentrated *in vacuo*. The crude residue was purified by column to yield the desired compounds (82% yield) as a white solid. **MP**: 197 – 198 °C. **¹H NMR** (500 MHz, CDCl₃): δ 7.92 – 7.86 (m, 3H), 7.38 (qdd, *J* = 6.8, 4.1, 1.8 Hz, 2H), 7.33 (dd, *J* = 8.9, 1.5 Hz, 1H), 7.21 – 7.15 (m, 1H), 5.91 (s, 1H), 5.30 (br, 1H), 3.77 (s, 3H), 2.44 (s, 3H), 1.85 (s, 3H), 1.36 (s, 9H). **¹³C NMR** (125 MHz, CDCl₃): δ 153.61, 153.43, 151.23, 133.55, 132.76, 132.59, 132.11, 130.54, 129.28, 128.33, 127.21, 123.80, 123.75, 121.57, 121.13, 117.79, 114.76, 80.52, 60.13, 28.16, 16.59, 13.12. **HRMS (ESI)** *m/z* Calcd for [C₂₄H₂₆NO₄, M - H]⁻: 392.1868; Found: 392.1866.

Synthesis of 1q:




To a solution of **1a** (0.4 mmol) in acetone (4 mL) were added K_2CO_3 (0.2 mmol) and MeI (0.4 mmol). The reaction mixture was allowed to stir at room temperature overnight. The solvent was evaporated *in vacuo*. The crude residue was purified by column chromatography to produce the desired product **1q** (25% yield) as a syrup. 1H NMR (400 MHz, CD_2Cl_2): δ 7.93 (dd, $J = 9.1, 0.8$ Hz, 1H), 7.84 – 7.78 (m, 1H), 7.36 (d, $J = 9.1$ Hz, 1H), 7.34 – 7.32 (m, 1H), 7.32 – 7.25 (m, 2H), 7.10 – 7.05 (m, 1H), 5.64 (br, 1H), 3.79 (s, 3H), 3.67 (s, 3H), 2.49 (s, 3H), 2.32 (s, 3H), 1.70 (s, 3H). ^{13}C NMR (75 MHz, CD_2Cl_2): δ 154.66, 154.10, 132.73, 131.70, 131.40, 131.05, 130.73, 129.22, 128.35, 127.42, 126.93, 124.00, 123.51, 121.22, 117.39, 113.08, 59.76, 56.05, 39.03, 16.09, 13.05. HRMS (ESI) m/z Calcd for $[C_{21}H_{23}NNaO_4S, M + Na]^+$: 408.1240; Found: 408.1242.

Attempt of kinetic resolution of 1a catalyzed by NHC:



To a 4 mL vial was added the racemic **1a** (0.075 mmol), triazolium salt (0.0075 mmol) and 4Å MS (25 mg). The mixture was taken into the glovebox, where aldehyde (9 μ L, 0.052 mmol), anhydrous DCM (0.75 mL) and DIPEA (18 μ L, 0.075 mmol) were added. The reaction mixture was taken outside the glovebox. The vial was then sealed and the reaction mixture was allowed to stir at ambient temperature for 24 h. The crude reaction mixture was directly purified by silica gel column chromatography with hexanes/ethyl acetate (10:1 v/v) as eluent to afford the ester product and the recovered starting material in pure form.

Recovered 1a:





Syrup. 1H NMR (500 MHz, $CDCl_3$) δ 7.92 – 7.87 (m, 2H), 7.53 (s, 1H), 7.43 – 7.37 (m, 2H), 7.29 (d, $J = 8.9$ Hz, 1H), 7.14 – 7.12 (m, 1H), 5.82 (s, 1H), 5.29 (s, 1H), 3.80 (s, 3H), 2.73 (s, 3H), 2.44 (s, 3H),

1.91 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 155.01, 150.98, 133.24, 132.98, 132.43, 132.00, 131.17, 129.40, 128.77, 127.67, 124.19, 123.64, 123.15, 121.52, 117.78, 114.09, 60.15, 39.59, 16.58, 13.34. HRMS (ESI) m/z Calcd for $[\text{C}_{20}\text{H}_{20}\text{NO}_4\text{S}, \text{M} - \text{H}]^-$: 370.1119; Found: 370.1119.

Optical Rotation: $[\alpha]_D^{25} + 4.0$ ($c = 0.2$, CHCl_3). 26% ee (HPLC condition: Chiralcel AD-H column, n -Hexane/ i -PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 10.02$ min for major isomer, $t_R = 12.42$ min for minor isomer).


Supplementary Figure 1. HPLC Trace of 1a from NHC-Catalyzed Kinetic Resolution.




Syrup. ^1H NMR (500 MHz, CDCl_3) δ 8.03 – 8.02 (m, 1H), 7.99 – 7.95 (m, 1H), 7.57 – 7.42 (m, 3H), 7.36 – 7.30 (m, 2H), 6.06 (s, 1H), 3.76 (s, 3H), 2.66 (s, 3H), 2.42 (s, 3H), 2.24 – 2.21 (m, 2H), 2.00 – 1.88 (m, 1H), 1.87 (s, 3H), 0.81 (d, $J = 3.5$ Hz, 3H), 0.79 (d, $J = 3.5$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 171.53, 154.26, 146.53, 132.24, 132.12, 132.04, 131.95, 131.33, 130.53, 128.50, 127.41, 126.24, 124.94, 124.88, 124.80, 121.75, 120.61, 59.87, 42.95, 39.56, 25.63, 21.95, 21.91, 16.33, 13.25. HRMS (ESI) m/z Calcd for $[\text{C}_{25}\text{H}_{29}\text{NNaO}_5\text{S}, \text{M} + \text{Na}]^+$: 478.1658; Found: 478.1654.

Optical Rotation: $[\alpha]_D^{25} - 8.0$ ($c = 1.0$, CH_2Cl_2). 27% ee (HPLC condition: Chiralcel ID column, n -Hexane/ i -PrOH = 95:5, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 31.59$ min for major isomer, $t_R = 37.63$ min for minor isomer).

Supplementary Figure 2. HPLC Trace of Acylation Product from NHC-Catalyzed Kinetic Resolution.



Representative procedure for the kinetic resolution of 1 catalyzed by (DHQD)₂AQN:




To a 4 mL vial containing **1** (0.04 mmol) and (DHQD)₂AQN (7.0 mg, 20 mol%) were added CH₂Cl₂ (0.5 mL), CH₃CN (0.5 mL) and MBH carbonate (6 μL). The reaction mixture was allowed to stir for 24 h at 24 °C. The volatiles were removed *in vacuo* at 24 °C and the residue was purified by silica gel column chromatography with hexanes/ethyl acetate (10:1 v/v) as the eluent to afford the product **4** and unreacted starting material **1**.

For the preparation of authentic racemic products, DABCO was used instead of (DHQD)₂AQN following the same procedure.

Note: NMR for the products were taken at 80 °C in DMSO-d₆.

Characterization of compounds


Recovered 1a




Syrup. $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.92 – 7.87 (m, 2H), 7.53 (s, 1H), 7.43 – 7.37 (m, 2H), 7.29 (d, J = 8.9 Hz, 1H), 7.14 – 7.12 (m, 1H), 5.82 (s, 1H), 5.29 (s, 1H), 3.80 (s, 3H), 2.73 (s, 3H), 2.44 (s, 3H), 1.91 (s, 3H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 155.01, 150.98, 133.24, 132.98, 132.43, 132.00, 131.17, 129.40, 128.77, 127.67, 124.19, 123.64, 123.15, 121.52, 117.78, 114.09, 60.15, 39.59, 16.58, 13.34. **HRMS (ESI)** m/z Calcd for $[\text{C}_{20}\text{H}_{20}\text{NO}_4\text{S}, \text{M} - \text{H}]^-$: 370.1119; Found: 370.1119.

Optical Rotation: $[\alpha]_D^{25} + 12.0$ ($c = 0.2$, CHCl_3). The absolute configuration of **1a** was assigned by analogy to **1b**. 98% ee (HPLC condition: Chiralcel AD-H column, n -Hexane/ i -PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 8.60$ min for major isomer, $t_R = 10.66$ min for minor isomer).

Supplementary Figure 3. HPLC Trace of Recovered 1a.



Product 3a




Syrup. $^1\text{H NMR}$ (500 MHz, $\text{DMSO}-d_6$, 80 °C) δ 9.08 (br, 1H), 7.87 – 7.81 (m, 2H), 7.32 – 7.23 (m, 3H), 7.14 (s, 1H), 7.10 – 7.04 (m, 1H), 6.02 (s, 1H), 5.56 (s, 1H), 4.14 (d, J = 16.6 Hz, 1H), 4.05 (q, J = 7.2 Hz, 2H), 3.93 (d, J = 16.2 Hz, 1H), 3.75 (s, 3H), 2.47 (s, 3H), 2.35 (s, 3H), 1.74 (s, 3H), 1.17 (t, J = 7.1 Hz, 3H). $^{13}\text{C NMR}$ (125 MHz, $\text{DMSO}-d_6$, 80 °C) δ 166.07, 156.88, 152.29, 136.60, 135.84, 135.52, 133.94, 132.32, 132.03, 130.12, 129.75, 128.60, 128.24, 128.03, 126.50, 124.76, 123.15, 118.97,


117.97 , 60.72 , 60.03 , 50.37 , 40.18 , 16.22 , 14.26 , 13.35 . **HRMS (ESI)** m/z Calcd for $[C_{26}H_{29}NNaO_6S, M + Na]^+$: 506.1608; Found: 506.1604.

Optical Rotation: $[\alpha]^{25}_D$ - 28.0 ($c = 1.0$, CH_2Cl_2). 60% ee (HPLC condition: Chiralcel AD-H column, n -Hexane/ i -PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 9.15$ min for minor isomer, $t_R = 10.11$ min for major isomer).

Supplementary Figure 4. HPLC Trace of Product 3a.




Product 4a




Syrup. 1H NMR (500 MHz, $DMSO-d_6$, 80 °C) δ 9.05 (br, 1H), 7.84 – 7.80 (m, 2H), 7.33 – 7.22 (m, 3H), 7.13 (s, 1H), 7.08 – 7.03 (m, 1H), 5.94 (s, 1H), 5.50 (s, 1H), 4.09 (d, $J = 16.5$ Hz, 1H), 3.86 (d, $J = 16.5$ Hz, 1H), 3.73 (s, 3H), 2.45 (s, 3H), 2.34 (s, 3H), 1.72 (s, 3H), 1.38 (s, 9H). ^{13}C NMR (125 MHz, $DMSO-d_6$, 80 °C) δ 164.43 , 155.92 , 151.33 , 136.97 , 134.96 , 134.50 , 133.00 , 131.37 , 131.17 , 129.10 , 128.79 , 127.66 , 127.28 , 126.34 , 125.55 , 123.82 , 122.21 , 118.03 , 117.03 , 79.99 , 59.06 , 49.32 , 27.18 , 15.29 , 12.38 . **HRMS (ESI)** m/z Calcd for $[C_{28}H_{33}NNaO_6S, M + Na]^+$: 534.1921; Found: 534.1926.

Optical Rotation: $[\alpha]^{25}_D$ - 25.0 ($c = 0.5$, CH_2Cl_2). 65% ee (HPLC condition: Chiralcel ID column, n -Hexane/ i -PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 11.26$ min for major isomer, $t_R = 12.61$ min for minor isomer).

Supplementary Figure 5. HPLC Trace of Product 4a.




Recovered 1b




Syrup. ¹H NMR (500 MHz, CDCl₃): δ 8.21 (s, 1H), 7.83 – 7.79 (m, 1H), 7.53 (s, 1H), 7.42 (tt, *J* = 8.3, 3.4 Hz, 2H), 7.18 – 7.14 (m, 1H), 5.74 (s, 1H), 5.72 (s, 1H), 3.79 (s, 3H), 2.72 (s, 3H), 2.45 (s, 3H), 1.88 (s, 3H). ¹³C NMR (125 MHz, CDCl₃): δ 154.95, 147.02, 132.82, 132.72, 132.19, 132.12, 131.21, 129.84, 128.10, 127.78, 125.25, 124.94, 123.66, 121.76, 116.29, 112.43, 60.12, 39.52, 16.55, 13.40. HRMS (ESI) *m/z* Calcd for [C₂₀H₁₉NO₄SBr, M - H]⁻: 448.0224; Found: 448.0230.

Optical Rotation: [α]_D²⁵ + 12.0 (*c* = 0.4, CHCl₃). The absolute configuration of **1b** was assigned by conversion to **6a** followed by single crystal X-ray analysis. 98% ee (HPLC condition: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, *t*_R = 11.88 min for major isomer, *t*_R = 12.78 min for minor isomer).

Supplementary Figure 6. HPLC Trace of Recovered 1b.




Product 4b




White solid. **MP**: 112 - 113 °C. **¹H NMR** (500 MHz, DMSO-*d*₆, 80 °C): δ 8.41 (br, 1H), 8.29 (s, 1H), 7.85 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.35 (ddd, *J* = 8.1, 6.7, 1.4 Hz, 1H), 7.31 (ddd, *J* = 8.2, 6.8, 1.5 Hz, 1H), 7.19 (s, 1H), 7.02 (d, *J* = 8.2 Hz, 1H), 5.92 (s, 1H), 5.43 (s, 1H), 4.00 (d, *J* = 16.4 Hz, 1H), 3.87 (d, *J* = 16.4 Hz, 1H), 3.76 (s, 3H), 2.61 (s, 3H), 2.37 (s, 3H), 1.73 (s, 3H), 1.40 (s, 9H). **¹³C NMR** (125MHz, DMSO-*d*₆, 80 °C): δ 164.40 , 156.25 , 147.42 , 136.41 , 135.10 , 133.37 , 131.93 , 131.73 , 131.34 , 130.91 , 130.27 , 128.59 , 126.80 , 126.54 , 126.08 , 124.09 , 123.65 , 119.96 , 113.18 , 80.16 , 59.09 , 49.71 , 39.23 , 27.18 , 15.34 , 12.54 . **HRMS (ESI)** *m/z* Calcd for [C₂₈H₃₂BrNNaO₆S, M + Na]⁺: 612.1026; Found: 612.1022.

Optical Rotation: [α]_D²⁵ - 35.0 (*c* = 1.0, CH₂Cl₂). 73% ee (HPLC condition: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, *t*_R = 6.91 min for major isomer, *t*_R = 7.65 min minor for isomer).

Supplementary Figure 7. HPLC Trace of Product 4b.



Recovered 1c




Syrup. **¹H NMR** (400 MHz, CDCl₃): δ 7.69 – 7.67 (m, 1H), 7.42 (s, 1H), 7.28 (ddd, *J* = 8.1, 6.9, 1.3 Hz, 1H), 7.21 – 7.14 (m, 2H), 7.07 – 7.00 (m, 1H), 6.05 (s, 1H), 5.78 (s, 1H), 4.01 (s, 3H), 3.69 (s, 3H), 2.54 (s, 3H), 2.33 (s, 3H), 1.79 (s, 3H). **¹³C NMR** (100 MHz, CDCl₃): δ 154.86 , 146.87 , 143.00 , 132.04 , 132.02 , 131.02 , 129.27 , 127.91 , 127.37 , 125.86 , 125.39 , 124.75 , 123.45 , 121.75 , 114.93 , 106.69 ,


60.05 , 56.05 , 39.15 , 16.49 , 13.47 . **HRMS (ESI)** m/z Calcd for $[C_{21}H_{22}NO_5S, M - H]^-$: 400.1224; Found: 400.1231.

Optical Rotation: $[\alpha]_D^{25} - 13.0$ ($c = 0.2$, $CHCl_3$). The absolute configuration of **1c** was assigned by analogy to **1b**. 97% ee (HPLC condition: Chiralpak AD-H column, n -Hexane/ i -PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 17.36$ min for major isomer, $t_R = 23.88$ min for minor isomer).

Supplementary Figure 8. HPLC Trace of Recovered **1c**.




Product 4c




Syrup: 1H NMR (500 MHz, $DMSO-d_6$): δ 8.44 (br, 1H), 7.77 (d, $J = 8.1$ Hz, 1H), 7.40 (s, 1H), 7.27 (ddd, $J = 8.1, 6.8, 1.2$ Hz, 1H), 7.17 – 7.10 (m, 2H), 7.00 (d, $J = 8.4$ Hz, 1H), 5.95 (s, 1H), 5.50 (s, 1H), 4.07 (d, $J = 16.7$ Hz, 1H), 4.02 (s, 3H), 3.88 (d, $J = 16.4$ Hz, 1H), 3.74 (s, 3H), 2.46 (s, 3H), 2.35 (s, 3H), 1.73 (s, 3H), 1.40 (s, 9H). ^{13}C NMR (125 MHz, $DMSO-d_6$): δ 165.36 , 156.84 , 149.05 , 144.21 , 137.92 , 135.82 , 135.16 , 132.14 , 130.10 , 129.08 , 128.90 , 127.31 , 127.07 , 124.62 , 124.21 , 123.83 , 118.85 , 107.25 , 104.99 , 80.93 , 60.03 , 56.38 , 50.34 , 40.23 , 28.12 , 16.25 , 13.33 . **HRMS (ESI)** m/z Calcd for $[C_{29}H_{35}NNaO_7S, M + Na]^+$: 564.2026; Found: 564.2021.

Optical Rotation: $[\alpha]_D^{25} + 8.0$ ($c = 1.0$, CH_2Cl_2). 51% ee (HPLC condition: Chiralpak AD-H column, n -Hexane/ i -PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 13.47$ min for minor isomer, $t_R = 16.03$ min for major isomer).

Supplementary Figure 9. HPLC Trace of Product 4c.




Recovered 1d



Syrup. ¹H NMR (500 MHz, CDCl₃): δ 8.04 (d, *J* = 1.9 Hz, 1H), 7.81 (d, *J* = 9.0 Hz, 1H), 7.50 (s, 1H), 7.45 (dd, *J* = 9.0, 1.9 Hz, 1H), 7.31 (d, *J* = 9.0 Hz, 1H), 7.01 (d, *J* = 8.9 Hz, 1H), 5.79 (s, 1H), 5.44 (s, 1H), 3.79 (s, 3H), 2.75 (s, 3H), 2.43 (s, 3H), 1.87 (s, 3H). ¹³C NMR (125 MHz, CDCl₃): δ 155.05, 151.37, 133.51, 132.94, 131.91, 131.08, 130.84, 130.70, 130.47, 130.18, 125.04, 123.15, 121.55, 119.07, 117.94, 114.52, 60.16, 39.80, 16.59, 13.33. HRMS (ESI) *m/z* Calcd for [C₂₀H₁₉NO₄SBr, M - H]⁻: 448.0224; Found: 448.0222.


Optical Rotation: [α]_D²⁵ + 18.0 (*c* = 1.0, CHCl₃). The absolute configuration of **1d** was assigned by analogy to **1b**. 98% ee (HPLC condition: Chiralpak ID column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, *t*_R = 10.07 min for minor isomer, *t*_R = 11.51 min for major isomer).

Supplementary Figure 10. HPLC Trace of Recovered 1d.



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %	Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.826	BV	0.3536	1.01352e4	433.75708	48.4516	1	10.079	MM	0.4976	3.44885	1.15515e-1	1.1918
2	11.098	VB	0.6121	1.07830e4	268.20438	51.5484	2	11.514	BB	0.6177	285.92834	6.84037	98.8082


Product 4d




Syrup: $^1\text{H NMR}$ (500 MHz, $\text{DMSO-}d_6$, 80 °C): δ 9.31 (br, 1H), 8.07 (d, $J = 2.0$ Hz, 1H), 7.85 (d, $J = 8.9$ Hz, 1H), 7.37 – 7.32 (m, 2H), 7.15 (s, 1H), 7.00 (d, $J = 9.0$ Hz, 1H), 5.95 (s, 1H), 5.50 (s, 1H), 4.10 (d, $J = 16.5$ Hz, 1H), 3.90 (d, $J = 16.5$ Hz, 1H), 3.74 (s, 3H), 2.59 (s, 3H), 2.35 (s, 3H), 1.72 (s, 3H), 1.40 (s, 9H). $^{13}\text{C NMR}$ (125 MHz, $\text{DMSO-}d_6$, 80 °C): δ 165.35, 156.90, 152.87, 137.74, 135.98, 134.96, 132.62, 132.31, 131.86, 130.41, 129.96, 129.81, 129.27, 129.06, 127.44, 127.29, 120.18, 118.30, 116.19, 81.01, 60.04, 50.42, 40.49, 28.13, 16.24, 13.35. **HRMS (ESI)** m/z Calcd for $[\text{C}_{28}\text{H}_{32}\text{BrNNaO}_6\text{S}, \text{M} + \text{Na}]^+$: 612.1026; Found: 612.1029.

Optical Rotation: $[\alpha]_D^{25} - 20.0$ ($c = 1.0$, CH_2Cl_2). 66% ee (HPLC condition: Chiralpak ID column, n -Hexane/ i -PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 10.02$ min for major isomer, $t_R = 11.57$ min for minor isomer).

Supplementary Figure 11. HPLC Trace of Product 4d.




Recovered 1e




Syrup. $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 8.62 (d, $J = 1.6$ Hz, 1H), 8.00 (d, $J = 9.0$ Hz, 1H), 7.95 (dd, $J = 8.7, 1.8$ Hz, 1H), 7.49 (s, 1H), 7.36 (d, $J = 8.9$ Hz, 1H), 7.17 (d, $J = 8.8$ Hz, 1H), 5.92 (br, 1H), 5.83 (s, 1H), 3.98 (s, 3H), 3.78 (s, 3H), 2.73 (s, 3H), 2.42 (s, 3H), 1.87 (s, 3H). $^{13}\text{C NMR}$ (125MHz, CDCl_3): δ 167.14, 155.06, 153.31, 135.09, 133.44, 132.92, 132.57, 131.89, 131.80, 128.35, 127.04, 125.66, 123.45, 123.37, 121.64, 118.88, 114.58, 60.15, 52.31, 39.76, 16.58, 13.35. **HRMS (ESI)** m/z Calcd for $[\text{C}_{22}\text{H}_{22}\text{NO}_6\text{S}, \text{M} - \text{H}]^-$: 428.1173; Found: 428.1174.

Optical Rotation: $[\alpha]_D^{25} + 23.0$ ($c = 1.0$, CHCl_3). The absolute configuration of **1e** was assigned by analogy to **1b**. 95% ee (HPLC condition: Chiralpak AD-H column, n -Hexane/ i -PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 15.45$ min for minor isomer, $t_R = 19.40$ min for major isomer).

Supplementary Figure 12. HPLC Trace of Recovered 1e.




Product 4e




Syrup. $^1\text{H NMR}$ (500 MHz, $\text{DMSO}-d_6$, 80 °C): δ 9.60 (br, 1H), 8.54 (d, $J = 1.7$ Hz, 1H), 8.05 (d, $J = 8.9$ Hz, 1H), 7.73 (dt, $J = 8.9, 1.3$ Hz, 1H), 7.44 – 7.37 (m, 1H), 7.16 (s, 1H), 7.13 (d, $J = 8.9$ Hz, 1H), 5.93 (s, 1H), 5.48 (s, 1H), 4.08 (d, $J = 16.6$ Hz, 1H), 3.91 – 3.88 (m, 4H), 3.75 (s, 3H), 2.56 (s, 3H), 2.36 (s, 3H), 1.73 (s, 3H), 1.38 (s, 9H). $^{13}\text{C NMR}$ (125 MHz, $\text{DMSO}-d_6$, 80 °C): δ 165.97, 164.37, 155.96, 153.83, 136.75, 135.43, 135.06, 134.01, 131.34, 130.93, 130.51, 130.13, 129.48, 126.56, 126.40, 124.50, 124.33, 123.61, 118.97, 117.30, 80.02, 59.08, 51.21, 49.49, 27.13, 15.30, 12.39. **HRMS (ESI)** m/z Calcd for $[\text{C}_{30}\text{H}_{35}\text{NNaO}_8\text{S}, \text{M} + \text{Na}]^+$: 592.2083; Found: 592.2087.

Optical Rotation: $[\alpha]_D^{25} - 20.0$ ($c = 1.0$, CH_2Cl_2). 66% ee (HPLC condition: Chiralpak AD-H column, n -Hexane/ i -PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 13.49$ min for major isomer, $t_R = 15.85$ min for minor isomer).

Supplementary Figure 13. HPLC Trace of Product 4e.




Recovered 1f




Syrup. ¹H NMR (500 MHz, CDCl₃): δ 7.87 (d, *J* = 8.9 Hz, 1H), 7.75 (d, *J* = 8.7 Hz, 1H), 7.53 (s, 1H), 7.48 (dd, *J* = 8.7, 1.9 Hz, 1H), 7.30 (d, *J* = 9.0 Hz, 1H), 7.25 (d, *J* = 1.9 Hz, 1H), 5.76 (s, 1H), 5.41 (s, 1H), 3.81 (s, 3H), 2.80 (s, 3H), 2.45 (s, 3H), 1.90 (s, 3H). ¹³C NMR (125 MHz, CDCl₃): δ 155.01, 152.05, 133.78, 133.73, 132.99, 132.02, 131.12, 130.43, 127.79, 127.59, 125.24, 122.54, 122.27, 121.21, 118.36, 113.44, 60.20, 39.70, 16.64, 13.34. HRMS (ESI) *m/z* Calcd for [C₂₀H₁₉NO₄SBr, M - H]⁻: 448.0224; Found: 448.0232.

Optical Rotation: [α]_D²⁵ + 68.0 (*c* = 0.5, CHCl₃). The absolute configuration of **1f** was assigned by analogy to **1b**. 99% ee (HPLC condition: Chiralpak ID column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, *t_R* = 8.61 min for major isomer, *t_R* = 9.88 min for minor isomer).

Supplementary Figure 14. HPLC Trace of Recovered 1f.




Product 4f




Syrup. $^1\text{H NMR}$ (500 MHz, $\text{DMSO-}d_6$, 80 $^\circ\text{C}$): δ 9.40 (br, 1H), 7.87 (d, J = 8.9 Hz, 1H), 7.79 (d, J = 8.7 Hz, 1H), 7.37 (dd, J = 8.7, 2.0 Hz, 1H), 7.33 (d, J = 8.9 Hz, 1H), 7.23 (s, 1H), 7.15 (s, 1H), 5.96 (s, 1H), 5.49 (s, 1H), 4.08 (d, J = 16.4 Hz, 1H), 3.91 (d, J = 16.4 Hz, 1H), 3.75 (s, 3H), 2.60 (s, 3H), 2.36 (s, 3H), 1.74 (s, 3H), 1.40 (s, 9H). $^{13}\text{C NMR}$ (125 MHz, $\text{DMSO-}d_6$): δ 165.33, 156.90, 153.41, 137.70, 136.07, 135.27, 134.83, 132.31, 131.82, 130.51, 130.34, 129.92, 127.60, 127.05, 126.94, 126.15, 120.48, 119.49, 117.35, 81.03, 60.05, 50.49, 40.54, 28.14, 16.27, 13.37. **HRMS (ESI)** m/z Calcd for $[\text{C}_{28}\text{H}_{32}\text{BrNNaO}_6\text{S}, \text{M} + \text{Na}]^+$: 612.1026; Found: 612.1024.

Optical Rotation: $[\alpha]_D^{25}$ - 22.0 (c = 1.0, CH_2Cl_2). 53% ee (HPLC condition: Chiralpak AD-H column, n -Hexane/ i -PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, t_R = 7.36 min for major isomer, t_R = 8.74 min for minor isomer).

Supplementary Figure 15. HPLC Trace of Product 4f.




Recovered 1g




Syrup. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.82 (d, J = 8.8 Hz, 1H), 7.78 (d, J = 8.9 Hz, 1H), 7.53 (s, 1H), 7.13 (d, J = 8.8 Hz, 1H), 7.07 (dd, J = 8.9, 2.5 Hz, 1H), 6.41 (d, J = 2.5 Hz, 1H), 5.84 (s, 1H), 5.09 (br, 1H), 3.80 (s, 3H), 3.71 (s, 3H), 2.76 (s, 3H), 2.44 (s, 3H), 1.94 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 159.29, 155.09, 151.53, 133.87, 133.25, 132.88, 132.01, 130.89, 130.39, 124.75, 123.67, 121.67, 115.79, 115.07, 113.22, 102.55, 60.13, 55.28, 39.62, 16.59, 13.25. **HRMS (ESI)** m/z Calcd for $[\text{C}_{21}\text{H}_{22}\text{NO}_5\text{S}, \text{M} - \text{H}]^-$: 400.1224; Found: 400.1231.

Optical Rotation: $[\alpha]_D^{25} + 28.0$ ($c = 0.2$, CHCl_3). The absolute configuration of **1g** was assigned by analogy to **1b**. 98% ee (HPLC condition: Chiralpak AD-H column, n -Hexane/ i -PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 9.44$ min for major isomer, $t_R = 14.68$ min for minor isomer).

Supplementary Figure 16. HPLC Trace of Recovered 1g.




Product 4g




Syrup. $^1\text{H NMR}$ (500 MHz, $\text{DMSO-}d_6$, 80 °C): δ 9.08 (br, 1H), 7.75 (d, $J = 8.8$ Hz, 1H), 7.73 (d, $J = 8.9$ Hz, 1H), 7.16 – 7.11 (m, 2H), 6.93 (dd, $J = 8.9, 2.5$ Hz, 1H), 6.43 (d, $J = 2.5$ Hz, 1H), 5.97 (s, 1H), 5.55 (s, 1H), 4.11 (d, $J = 16.7$ Hz, 1H), 3.90 (d, $J = 16.6$ Hz, 1H), 3.73 (s, 3H), 3.60 (s, 3H), 2.51 (s, 3H), 2.35 (s, 3H), 1.75 (s, 3H), 1.39 (s, 9H). $^{13}\text{C NMR}$ (125 MHz, $\text{DMSO-}d_6$, 80 °C): δ 165.37, 158.25, 156.92, 152.87, 137.88, 135.89, 135.57, 135.40, 132.24, 132.17, 129.91, 129.79, 129.48, 127.20, 124.02, 117.25, 116.33, 115.31, 104.36, 80.95, 60.01, 55.12, 50.22, 40.30, 28.10, 16.27, 13.25. **HRMS (ESI)** m/z Calcd for $[\text{C}_{29}\text{H}_{35}\text{NNaO}_7\text{S}, \text{M} + \text{Na}]^+$: 564.2026; Found: 564.2029.

Optical Rotation: $[\alpha]_D^{25} - 25.0$ ($c = 1.0$, CH_2Cl_2). 68% ee (HPLC condition: Chiralpak OD-H column, n -Hexane/ i -PrOH = 98:2, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 17.62$ min for minor isomer, $t_R = 21.06$ min for major isomer).

Supplementary Figure 17. HPLC Trace of Product 4g.




Recovered 1h



Syrup. $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 7.87 (d, $J = 8.9$ Hz, 1H), 7.84 (d, $J = 8.0$ Hz, 1H), 7.56 (s, 1H), 7.40 (dd, $J = 8.6, 2.2$ Hz, 2H), 7.36 (ddd, $J = 8.0, 6.8, 1.2$ Hz, 1H), 7.23 (d, $J = 8.8$ Hz, 1H), 7.21 – 7.17 (m, 1H), 7.11 (d, $J = 8.1$ Hz, 2H), 6.81 – 6.75 (m, 1H), 6.11 (s, 1H), 4.86 (br, 1H), 3.75 (s, 3H), 2.40 (s, 6H), 1.78 (s, 3H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3): δ 154.52, 151.03, 143.82, 135.96, 132.89, 132.72, 132.39, 131.91, 131.01, 129.54, 129.21, 128.45, 127.42, 127.18, 123.78, 123.23, 122.68, 120.80, 117.64, 113.68, 60.10, 21.59, 16.60, 13.21. **HRMS (ESI)** m/z Calcd for $[\text{C}_{26}\text{H}_{24}\text{NO}_4\text{S}, \text{M} - \text{H}]^-$: 446.1432; Found: 446.1430.


Optical Rotation: $[\alpha]_D^{25} + 50.0$ ($c = 0.2$, CHCl_3). The absolute configuration of **1h** was assigned by analogy to **1b**. 95% ee (HPLC condition: Chiralpak ID column, n -Hexane/ i -PrOH = 80:20, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 9.36$ min for major isomer, $t_R = 11.38$ min for minor isomer).

Supplementary Figure 18. HPLC Trace of Recovered 1h.



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %	Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.238	BB	0.2915	854.86621	44.81683	48.2714	1	9.363	BB	0.2995	540.59430	27.60513	97.5562
2	11.271	BB	0.3659	916.09235	38.46063	51.7286	2	11.386	MM	0.4307	13.54197	5.24025e-1	2.4438


Product 4h




Syrup. $^1\text{H NMR}$ (500 MHz DMSO- d_6 , 80 °C): δ 8.90 (br, 1H), 7.84 – 7.78 (m, 2H), 7.28 (ddd, $J = 8.0$, 6.7, 1.3 Hz, 1H), 7.26 – 7.21 (m, 2H), 7.17 – 7.06 (m, 5H), 6.95 (s, 1H), 5.78 (s, 1H), 5.16 (s, 1H), 4.09 (d, $J = 16.6$ Hz, 1H), 3.82 (d, $J = 16.4$ Hz, 1H), 3.75 (s, 3H), 2.33 (s, 3H), 2.31 (s, 3H), 1.74 (s, 3H), 1.38 (s, 9H). $^{13}\text{C NMR}$ (125 MHz, DMSO- d_6 , 80 °C): δ 165.31, 156.92, 152.25, 143.43, 137.14, 137.06, 136.03, 135.80, 134.02, 132.51, 131.34, 129.90, 129.50, 129.41, 128.69, 128.17, 128.03, 127.66, 126.33, 125.09, 123.02, 118.88, 118.07, 80.79, 60.07, 50.67, 28.12, 21.28, 16.23, 13.41. **HRMS (ESI)** m/z Calcd for $[\text{C}_{34}\text{H}_{37}\text{NNaO}_6\text{S}, \text{M} + \text{Na}]^+$: 610.2234; Found: 610.2236.

Optical Rotation: $[\alpha]_D^{25} + 14.0$ ($c = 1.0$, CH_2Cl_2). 72% ee (HPLC condition: Chiralpak AD-H column, n -Hexane/ i -PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 11.97$ min for minor isomer, $t_R = 14.93$ min for major isomer).

Supplementary Figure 19. HPLC Trace of Product 4h.




Recovered 1i




Syrup. $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.78 – 8.75 (m, 1H), 8.75 – 8.71 (m, 1H), 8.41 (ddd, $J = 8.2, 1.5, 0.6$ Hz, 1H), 7.81 (ddd, $J = 8.4, 7.0, 1.5$ Hz, 1H), 7.73 (ddd, $J = 8.2, 7.0, 1.2$ Hz, 1H), 7.61 – 7.55 (m, 2H), 7.47 (ddd, $J = 8.2, 7.0, 1.2$ Hz, 1H), 7.15 (ddd, $J = 8.1, 1.4, 0.6$ Hz, 1H), 5.89 (s, 1H), 5.38 (s, 1H), 3.82 (s, 3H), 2.76 (s, 3H), 2.48 (s, 3H), 1.97 (s, 3H). $^{13}\text{C NMR}$ (100MHz, CDCl_3): δ 155.09 , 147.39 , 133.67 , 133.40 , 132.52 , 131.69 , 130.70 , 128.15 , 127.72 , 127.14 , 127.01 , 125.00 , 124.72 , 123.76 , 123.35 , 123.28 , 122.96 , 122.74 , 121.27 , 110.06 , 60.20 , 39.72 , 16.64 , 13.34 . **HRMS (ESI)** m/z Calcd for $[\text{C}_{24}\text{H}_{22}\text{NO}_4\text{S}, \text{M} - \text{H}]^-$: 420.1276; Found: 420.1274.

Optical Rotation: $[\alpha]_D^{25} + 16.0$ ($c = 0.4$, CHCl_3). The absolute configuration of **1i** was assigned by analogy to **1b**. 99% ee (HPLC condition: Chiralpak AD-H column, n -Hexane/ i -PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 10.45$ min for major isomer, $t_R = 21.85$ min for minor isomer).

Supplementary Figure 20. HPLC Trace of Recovered 1i.



Product 4i




Syrup. $^1\text{H NMR}$ (500 MHz, $\text{DMSO}-d_6$, 80 °C): δ 8.84 (d, $J = 8.2$ Hz, 1H), 8.76 (d, $J = 8.2$ Hz, 1H), 8.41 (dd, $J = 8.2, 1.5$ Hz, 1H), 7.77 (ddd, $J = 8.4, 7.0, 1.5$ Hz, 1H), 7.71 (ddd, $J = 8.2, 7.0, 1.3$ Hz, 1H), 7.50 (ddd, $J = 8.3, 6.9, 1.4$ Hz, 1H), 7.40 (ddd, $J = 8.1, 6.9, 1.3$ Hz, 1H), 7.21 (s, 1H), 7.08 (dd, $J = 8.3, 1.3$ Hz, 1H), 5.88 (s, 1H), 5.48 (s, 1H), 4.04 (d, $J = 16.4$ Hz, 1H), 3.87 (d, $J = 16.4$ Hz, 1H), 3.78 (d, $J = 1.4$ Hz, 3H), 2.59 (s, 3H), 2.39 (s, 3H), 1.80 (s, 3H), 1.37 (s, 9H). $^{13}\text{C NMR}$ (125 MHz, $\text{DMSO}-d_6$, 80 °C): δ 165.42 , 157.32 , 147.55 , 137.43 , 136.22 , 134.85 , 133.13 , 132.67 , 132.07 , 131.42 , 131.02 , 127.89 , 127.70 , 127.28 , 126.95 , 126.71 , 126.48 , 125.33 , 124.54 , 123.47 , 123.24 , 123.23 , 115.26 , 81.12 , 60.04 , 50.46 , 28.10 , 16.33 , 13.50 . **HRMS (ESI)** m/z Calcd for $[\text{C}_{32}\text{H}_{35}\text{NNaO}_6\text{S}, \text{M} + \text{Na}]^+$: 584.2077; Found: 584.2074.


Optical Rotation: $[\alpha]_D^{25} + 16.0$ ($c = 1.0$, CH_2Cl_2). 68% ee (HPLC condition: Chiralpak IE column, n -Hexane/ i -PrOH = 95:5, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 24.80$ min for

minor isomer, $t_R = 26.78$ min for major isomer).

Supplementary Figure 21. HPLC Trace of Product 4i.




Recovered 1j



Syrup. $^1\text{H NMR}$ (500 MHz, Acetone- d_6): δ 9.07 (br, 1H), 7.45 (d, $J = 1.9$ Hz, 1H), 7.41 (s, 1H), 7.24 (d, $J = 1.9$ Hz, 1H), 7.05 (br, 1H), 3.73 (s, 3H), 2.92 (s, 3H), 2.34 (s, 3H), 1.95 (s, 3H). $^{13}\text{C NMR}$ (125MHz, Acetone- d_6): δ 156.80, 154.35, 131.53, 131.50, 130.81, 127.81, 126.45, 126.25, 124.33, 122.43, 121.93, 118.63, 59.32, 39.41, 15.65, 12.60. **HRMS (ESI)** m/z Calcd for $[\text{C}_{16}\text{H}_{16}\text{Br}_2\text{NO}_4\text{S}, \text{M} - \text{H}]^-$: 475.9173; Found: 475.9175.


Optical Rotation: $[\alpha]_D^{25} + 22.0$ ($c = 1.0$, CHCl_3). The absolute configuration of **1j** was assigned by analogy to **1b**. 73% ee (HPLC condition: Chiralpak AD-H column, n -Hexane/ i -PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 6.58$ min for major isomer, $t_R = 7.85$ min for minor isomer).

Supplementary Figure 22. HPLC Trace of Recovered 1j.



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %	Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.664	BB	0.2563	253.79059	14.78525	49.8633	1	6.582	BB	0.2548	274.68600	16.19757	86.3502
2	7.986	MM	0.3264	255.18239	13.03028	50.1367	2	7.850	BB	0.2960	43.42095	2.26197	13.6498


Product 4j




Syrup. ¹H NMR (500 MHz, DMSO-*d*₆, 80 °C): δ 9.94 (br, 1H), 7.36 (s, 1H), 7.18 (s, 1H), 7.15 (s, 1H), 6.05 (s, 1H), 5.59 (s, 1H), 4.15 (s, 2H), 3.71 (s, 3H), 2.94 (s, 3H), 2.30 (s, 3H), 1.86 (s, 3H), 1.44 (s, 9H). ¹³C NMR (125MHz, DMSO-*d*₆, 80 °C): δ 165.28 , 157.36 , 156.70 , 137.84 , 135.54 , 135.07 , 131.48 , 130.82 , 126.72 , 126.68 , 126.52 , 125.65 , 125.17 , 121.97 , 118.65 , 81.03 , 60.03 , 50.70 , 40.55 , 28.20 , 16.23 , 13.38 . **HRMS (ESI)** m/z Calcd for [C₂₄H₂₉Br₂NNaO₆S, M + Na]⁺: 639.9974; Found: 639.9978.

Optical Rotation: [α]_D²⁵ + 21.0 (*c* = 1.0, CH₂Cl₂). 83% ee (HPLC condition: Chiralpak As-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, *t*_R = 5.65 min for major isomer, *t*_R = 6.68 min for minor isomer).

Supplementary Figure 23. HPLC Trace of Product 4j.




Recovered 1k




White solid. **Mp**: 229 – 231 °C. **¹H NMR** (400 MHz, CDCl₃): δ 7.42 (s, 1H), 6.84 (s, 1H), 5.85 (s, 1H), 4.83 (s, 1H), 3.75 (s, 3H), 2.91 (s, 3H), 2.46 (s, 3H), 2.38 (s, 3H), 2.06 (s, 3H), 1.93 (s, 3H). **¹³C NMR** (100MHz, CDCl₃): δ 154.65 , 151.58 , 140.61 , 137.62 , 133.09 , 132.09 , 131.34 , 124.58 , 120.34 , 120.26 , 119.74 , 116.00 , 60.11 , 39.78 , 24.20 , 20.82 , 16.52 , 13.28 . **HRMS (ESI)** m/z Calcd for [C₁₈H₂₁ BrNO₄S, M - H]: 426.0381; Found: 426.0384.

Optical Rotation: [α]²⁵_D - 17.0 (*c* = 1.0, CHCl₃). The absolute configuration of **1k** was assigned by analogy to **1b**. 84% ee (HPLC condition: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, *t*_R = 6.26 min for major isomer, *t*_R = 11.56 min for minor isomer).

Supplementary Figure 24. HPLC Trace of Recovered **1k**.




Product 4k




Syrup. **¹H NMR** (500 MHz, DMSO-*d*₆, 80 °C): δ 8.95 (s, 1H), 7.05 (s, 1H), 6.82 (s, 1H), 6.06 (s, 1H), 5.64 (s, 1H), 4.18 (d, *J* = 16.5 Hz, 1H), 4.05 (d, *J* = 16.5 Hz, 1H), 3.71 (s, 3H), 2.87 (s, 3H), 2.39 (s, 3H), 2.30 (s, 3H), 1.97 (s, 3H), 1.81 (s, 3H), 1.43 (s, 9H). **¹³C NMR** (125 MHz, DMSO-*d*₆, 80 °C): δ 165.55 , 156.76 , 153.71 , 138.03 , 137.92 , 137.77 , 136.90 , 135.17 , 131.57 , 131.40 , 130.01 , 127.87 , 124.95 , 117.48 , 116.15 , 81.12 , 59.98 , 50.31 , 40.71 , 28.17 , 23.95 , 21.67 , 16.14 , 13.40 . **HRMS (ESI)** m/z Calcd for [C₂₆H₃₄BrNNaO₆S, M + Na]⁺: 590.1182; Found: 590.1183.

Optical Rotation: [α]²⁵_D + 12.0 (*c* = 1.0, CH₂Cl₂). 66% ee (HPLC condition: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, *t*_R = 6.28 min for minor isomer, *t*_R = 13.76 min for major isomer).

Supplementary Figure 25. HPLC Trace of Product 4k.




Recovered 11




Syrup. ¹H NMR (400 MHz, Acetone-*d*₆): δ 8.52 (br, 1H), 7.91 – 7.86 (m, 2H), 7.49 (t, *J* = 8.2 Hz, 1H), 7.42 (dd, *J* = 8.3, 1.1 Hz, 1H), 7.40 – 7.30 (m, 3H), 7.21 (ddd, *J* = 7.4, 2.2, 0.9 Hz, 1H), 7.01 (dd, *J* = 8.2, 1.2 Hz, 1H), 6.61 (br, 1H), 3.65 (s, 3H), 2.79 (s, 3H). ¹³C NMR (100MHz, Acetone-*d*₆): δ 158.77, 152.72, 137.80, 133.81, 130.31, 129.79, 129.07, 128.23, 126.70, 123.81, 123.19, 118.47, 115.69, 112.46, 112.29, 107.51, 55.22, 38.88. HRMS (ESI) *m/z* Calcd for [C₁₈H₁₆NO₄S, M - H]⁻: 342.0806; Found: 342.0808.

Optical Rotation: [α]_D²⁵ + 8.0 (*c* = 0.2, CHCl₃). The absolute configuration of **11** was assigned by analogy to **1b**. 95% ee (HPLC condition: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, *t*_R = 14.18 min for major isomer, *t*_R = 18.24 min for minor isomer).

Supplementary Figure 26. HPLC Trace of Recovered 11.




Product 4l




Syrup. $^1\text{H NMR}$ (500 MHz, $\text{DMSO-}d_6$, 80 °C) δ 9.01 (s, 1H), 7.81 (td, $J = 7.4, 1.1$ Hz, 2H), 7.45 (t, $J = 8.2$ Hz, 1H), 7.27 (d, $J = 8.8$ Hz, 1H), 7.26 – 7.21 (m, 2H), 7.16 (dd, $J = 8.4, 1.1$ Hz, 1H), 7.10 (ddd, $J = 9.1, 7.4, 1.3$ Hz, 2H), 5.95 (d, $J = 1.4$ Hz, 1H), 5.52 (d, $J = 1.4$ Hz, 1H), 4.12 (d, $J = 16.5$ Hz, 1H), 3.88 (d, $J = 16.5$ Hz, 1H), 3.58 (s, 3H), 2.53 (s, 3H), 1.39 (s, 9H). $^{13}\text{C NMR}$ (125 MHz, $\text{DMSO-}d_6$, 80 °C) δ 165.26, 159.44, 152.68, 141.36, 137.81, 134.48, 129.52, 128.89, 128.52, 128.07, 127.17, 126.13, 125.79, 125.08, 124.53, 122.94, 118.94, 115.44, 112.00, 80.97, 56.58, 50.03, 40.70, 28.14. **HRMS (ESI)** m/z Calcd for $[\text{C}_{26}\text{H}_{29}\text{NNaO}_6\text{S}, \text{M} + \text{Na}]^+$: 506.1608; Found: 506.1606.

Optical Rotation: $[\alpha]^{25}_{\text{D}} + 12.0$ ($c = 0.5$, CH_2Cl_2). 68% ee (HPLC condition: Chiralpak OD-H column, n -Hexane/ i -PrOH = 95:5, flow rate = 0.7 mL/min, wavelength = 254 nm, $t_{\text{R}} = 22.15$ min for minor isomer, $t_{\text{R}} = 26.30$ min for major isomer).

Supplementary Figure 27. HPLC Trace of Product 4l.



Recovered 1m




White solid. **MP:** 181 – 182 °C. $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.15 (d, $J = 9.0$ Hz, 1H), 8.02 (d, $J = 9.1$ Hz, 1H), 7.99 (d, $J = 9.0$ Hz, 1H), 7.91 (d, $J = 8.2$ Hz, 2H), 7.48 (d, $J = 8.2$ Hz, 2H), 7.45 – 7.41 (m, 1H), 7.38 (ddd, $J = 8.1, 7.0, 1.1$ Hz, 1H), 7.32 (d, $J = 8.9$ Hz, 1H), 7.29 – 7.25 (m, 1H), 7.16 – 7.10 (m, 3H), 7.05 (d, $J = 8.5$ Hz, 1H), 6.66 (d, $J = 8.5$ Hz, 1H), 6.50 (br, 1H), 4.62 (br, 1H), 2.37 (s, 3H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 151.87, 144.09, 135.85, 134.67, 132.96, 131.56, 131.14, 130.66, 129.67, 129.31, 128.45, 128.27, 127.61, 127.51, 127.23, 125.65, 125.26, 123.96, 123.72, 119.12, 118.26, 117.80, 111.89, 21.56. **HRMS (ESI)** m/z Calcd for $[\text{C}_{27}\text{H}_{21}\text{NO}_3\text{S}, \text{M} - \text{H}]^-$: 438.1170; Found: 438.1174.


Optical Rotation: $[\alpha]^{25}_{\text{D}} + 30.0$ ($c = 0.5$, CH_2Cl_2). The absolute configuration of **1m** was assigned by analogy to **1b**. 98% ee (HPLC condition: Chiralcel AD-H column, n -Hexane/ i -PrOH =

80:20, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 7.11$ min for minor isomer, $t_R = 7.83$ min for major isomer).

Supplementary Figure 28. HPLC Trace of Recovered 1m.




Product 4m



Syrup. $^1\text{H NMR}$ (500 MHz, $\text{DMSO-}d_6$, 80 °C) δ 9.13 (br, 1H), 8.02 (dd, $J = 9.0, 2.1$ Hz, 2H), 7.92 (d, $J = 8.9$ Hz, 1H), 7.89 (d, $J = 8.1$ Hz, 1H), 7.56 – 7.46 (m, 2H), 7.34 – 7.26 (m, 3H), 7.23 – 7.18 (m, 2H), 7.15 – 7.05 (m, 4H), 6.90 (d, $J = 8.5$ Hz, 1H), 5.79 (s, 1H), 5.21 (s, 1H), 4.25 (d, $J = 16.5$ Hz, 1H), 3.96 (d, $J = 16.4$ Hz, 1H), 2.34 (s, 3H), 1.37 (s, 9H). $^{13}\text{C NMR}$ (125 MHz, $\text{DMSO-}d_6$, 80 °C) δ 165.20, 153.16, 143.62, 138.33, 137.15, 134.70, 134.39, 134.14, 133.04, 130.04, 129.74, 129.55, 129.22, 128.62, 128.32, 128.26, 128.17, 128.07, 127.58, 126.81, 126.78, 126.70, 126.36, 125.63, 123.08, 118.82, 116.35, 80.87, 50.52, 28.14, 21.31. **HRMS (ESI)** m/z Calcd for $[\text{C}_{35}\text{H}_{33}\text{NNaO}_5\text{S}, \text{M} + \text{Na}]^+$: 602.1971; Found: 602.1975.


Optical Rotation: $[\alpha]_D^{25} - 36.0$ ($c = 1.0$, CH_2Cl_2). 71% ee (HPLC condition: Chiralcel AD-H column, n -Hexane/ i -PrOH = 80:20, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 17.40$ min for major isomer, $t_R = 21.82$ min for minor isomer).

Supplementary Figure 29. HPLC Trace of Product 4m.



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %	Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	17.678	BB	0.5827	338.86722	8.87109	50.0496	1	17.402	BB	0.5782	934.78473	24.83263	85.6904
2	21.356	BB	0.7838	338.19522	6.46997	49.9504	2	21.821	BV	0.7811	156.10153	2.93678	14.3096


Recovered 1n




White solid. **MP**: 201–202 °C. **¹H NMR** (500 MHz, CDCl₃) δ 8.10 (d, *J* = 9.0 Hz, 1H), 7.96 (d, *J* = 8.9 Hz, 1H), 7.90 (t, *J* = 8.7 Hz, 2H), 7.43 (d, *J* = 8.2 Hz, 2H), 7.36 (ddd, *J* = 8.1, 6.7, 1.1 Hz, 1H), 7.29 (d, *J* = 9.1 Hz, 1H), 7.20 (d, *J* = 2.2 Hz, 1H), 7.11 (ddd, *J* = 8.3, 6.8, 1.3 Hz, 1H), 7.07 (d, *J* = 8.0 Hz, 2H), 6.96–6.91 (m, 2H), 6.64 (d, *J* = 8.4 Hz, 1H), 6.43 (br, 1H), 4.75 (br, 1H), 3.91 (s, 3H), 2.36 (s, 3H). **¹³C NMR** (125 MHz, CDCl₃) δ 157.55, 151.76, 143.94, 135.87, 132.99, 132.57, 132.50, 131.42, 129.61, 129.24, 129.21, 128.40, 128.19, 127.46, 127.15, 127.00, 123.87, 123.75, 120.43, 120.17, 119.34, 117.78, 112.22, 106.35, 55.40, 29.73. **HRMS (ESI)** *m/z* Calcd for [C₂₈H₂₃NO₄S, M - H]⁻: 468.1276; Found: 468.1272.

Optical Rotation: [α]_D²⁵ + 30.0 (*c* = 0.5, CH₂Cl₂). The absolute configuration of **1n** was assigned by analogy to **1b**. 99% ee (HPLC condition: Chiralcel AD-H column, *n*-Hexane/*i*-PrOH = 80:20, flow rate = 1.0 mL/min, wavelength = 254 nm, *t*_R = 8.37 min for minor isomer, *t*_R = 10.35 min for major isomer).

Supplementary Figure 30. HPLC Trace of Recovered 1n.




Product 4n




Syrup. $^1\text{H NMR}$ (500 MHz, $\text{DMSO-}d_6$, 80 °C) δ 9.07 (br, 1H), 7.93 – 7.84 (m, 3H), 7.44 – 7.39 (m, 2H), 7.31 (d, $J = 8.9$ Hz, 1H), 7.27 (ddd, $J = 8.1, 6.8, 1.2$ Hz, 1H), 7.20 (d, $J = 7.9$ Hz, 2H), 7.13 (ddd, $J = 8.4, 6.8, 1.4$ Hz, 1H), 7.09 (d, $J = 8.0$ Hz, 2H), 6.99 – 6.93 (m, 2H), 6.93 – 6.88 (m, 1H), 5.79 (d, $J = 1.4$ Hz, 1H), 5.20 (d, $J = 1.4$ Hz, 1H), 4.23 (d, $J = 16.4$ Hz, 1H), 3.96 (dd, $J = 16.4, 1.2$ Hz, 1H), 3.91 (s, 3H), 2.34 (s, 3H), 1.38 (s, 9H). $^{13}\text{C NMR}$ (125 MHz, $\text{DMSO-}d_6$, 80 °C) δ 165.23, 158.36, 153.07, 143.54, 137.18, 136.17, 134.73, 134.49, 134.39, 129.96, 129.71, 129.52, 129.38, 128.58, 128.38, 128.14, 128.03, 127.56, 127.20, 126.74, 126.32, 125.68, 123.06, 119.09, 118.80, 116.53, 107.21, 80.85, 55.88, 50.54, 28.14, 21.31. **HRMS (ESI)** m/z Calcd for $[\text{C}_{36}\text{H}_{35}\text{NNaO}_6\text{S}, \text{M} + \text{Na}]^+$: 632.2077; Found: 632.2072.

Optical Rotation: $[\alpha]_D^{25} - 55.0$ ($c = 1.0$, CH_2Cl_2). 68% ee (HPLC condition: Chiralcel AD-H column, n -Hexane/ i -PrOH = 80:20, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 16.42$ min for major isomer, $t_R = 30.40$ min for minor isomer).

Supplementary Figure 31. HPLC Trace of Product **4n**.



Recovered **1o**




White solid. **MP:** 224 – 225 °C. $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.63 (d, $J = 1.6$ Hz, 1H), 8.16 (d, $J = 9.0$ Hz, 1H), 8.08 (d, $J = 8.9$ Hz, 1H), 8.04 (d, $J = 9.0$ Hz, 1H), 7.96 – 7.88 (m, 1H), 7.60 (dd, $J = 8.8, 1.7$ Hz, 1H), 7.48 – 7.37 (m, 4H), 7.29 – 7.24 (m, 1H), 7.06 (d, $J = 8.0$ Hz, 2H), 7.02 – 6.94 (m, 1H), 6.57 (d, $J = 8.8$ Hz, 1H), 6.47 (br, 1H), 5.12 (br, 1H), 3.99 (s, 3H), 2.36 (s, 3H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 167.07, 153.97, 144.30, 135.87, 135.59, 134.68, 132.95, 132.85, 131.36, 131.20, 130.92, 129.68,


128.37 , 128.25 , 127.73 , 127.07 , 126.86 , 125.78 , 125.42 , 125.07 , 123.90 , 119.41 , 118.78 , 117.89 , 112.38 , 52.25 , 21.48 . **HRMS (ESI)** m/z Calcd for $[C_{29}H_{23}NO_5S, M - H]^-$: 496.1225; Found: 496.1228.

Optical Rotation: $[\alpha]^{25}_D + 15.0$ ($c = 0.5$, CH_2Cl_2). The absolute configuration of **1o** was assigned by analogy to **1b**. 97% ee (HPLC condition: Chiralcel AD-H column, *n*-Hexane/*i*-PrOH = 80:20, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 8.74$ min for major isomer, $t_R = 11.59$ min for minor isomer).

Supplementary Figure 32. HPLC Trace of Recovered **1o**.




Product 4o




Syrup. 1H NMR (500 MHz, $DMSO-d_6$, 80 °C) δ 9.67 (br, 1H), 8.58 (d, $J = 1.7$ Hz, 1H), 8.12 (d, $J = 8.9$ Hz, 1H), 8.03 (d, $J = 8.6$ Hz, 2H), 7.58 (dd, $J = 9.0, 1.8$ Hz, 1H), 7.56 – 7.52 (m, 1H), 7.46 (d, $J = 8.8$ Hz, 1H), 7.42 (d, $J = 8.9$ Hz, 1H), 7.34 – 7.29 (m, 1H), 7.26 (d, $J = 8.0$ Hz, 2H), 7.12 (d, $J = 8.0$ Hz, 2H), 7.03 (d, $J = 8.5$ Hz, 1H), 6.91 (d, $J = 8.9$ Hz, 1H), 5.79 (s, 1H), 5.23 (s, 1H), 4.27 (d, $J = 16.5$ Hz, 1H), 4.03 (d, $J = 16.6$ Hz, 1H), 3.90 (s, 3H), 2.34 (s, 3H), 1.36 (s, 9H). ^{13}C NMR (125 MHz, $DMSO-d_6$, 80 °C) δ 166.97 , 165.11 , 155.67 , 143.68 , 138.45 , 137.25 , 137.13 , 133.94 , 133.92 , 133.06 , 131.78 , 130.95 , 129.60 , 129.13 , 128.68 , 128.36 , 128.02 , 127.47 , 126.99 , 126.93 , 126.51 , 125.97 , 125.30 , 124.45 , 119.79 , 116.56 , 80.91 , 52.20 , 50.92 , 28.10 , 21.29 . **HRMS (ESI)** m/z Calcd for $[C_{37}H_{35}NNaO_7S, M + Na]^+$: 660.2026; Found: 660.2022.

Optical Rotation: $[\alpha]^{25}_D - 42.0$ ($c = 1.0$, CH_2Cl_2). 73% ee (HPLC condition: Chiralcel IA column, *n*-Hexane/*i*-PrOH = 80:20, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 17.16$ min for minor isomer, $t_R = 19.11$ min for major isomer).

Supplementary Figure 33. HPLC Trace of Product 4o.




Recovered 1p




White solid. **MP:** 197 – 198 °C. **¹H NMR** (500 MHz, CDCl₃): δ 7.92 – 7.86 (m, 3H), 7.38 (qdd, *J* = 6.8, 4.1, 1.8 Hz, 2H), 7.33 (dd, *J* = 8.9, 1.5 Hz, 1H), 7.21 – 7.15 (m, 1H), 5.91 (s, 1H), 5.30 (br, 1H), 3.77 (s, 3H), 2.44 (s, 3H), 1.85 (s, 3H), 1.36 (s, 9H). **¹³C NMR** (125 MHz, CDCl₃): δ 153.61, 153.43, 151.23, 133.55, 132.76, 132.59, 132.11, 130.54, 129.28, 128.33, 127.21, 123.80, 123.75, 121.57, 121.13, 117.79, 114.76, 80.52, 60.13, 28.16, 16.59, 13.12. **HRMS (ESI)** *m/z* Calcd for [C₂₄H₂₆NO₄, M - H]: 392.1868; Found: 392.1866.

Optical Rotation: [α]_D²⁵ + 20.0 (*c* = 0.4, CHCl₃). 19% ee (HPLC condition: Chiralpak ID column, *n*-Hexane/*i*-PrOH = 95:5, flow rate = 1.0 mL/min, wavelength = 254 nm, *t*_R = 5.62 min for major isomer, *t*_R = 6.21 min for minor isomer).

Supplementary Figure 34. HPLC Trace of Recovered 1p.




Product 4p




Syrup. $^1\text{H NMR}$ (500 MHz, $\text{DMSO-}d_6$, 80 °C): δ 8.04 (d, $J = 9.0$ Hz, 1H), 7.97 – 7.91 (m, 1H), 7.56 – 7.52 (m, 2H), 7.38 (dddd, $J = 13.7, 6.8, 5.2, 1.5$ Hz, 2H), 7.17 – 7.11 (m, 1H), 6.28 (s, 1H), 6.04 (s, 1H), 5.55 (s, 1H), 4.86 – 4.71 (m, 2H), 3.70 (s, 3H), 2.35 (s, 3H), 1.74 (s, 3H), 1.45 (s, 9H), 1.23 (s, 9H). $^{13}\text{C NMR}$ (125 MHz, $\text{DMSO-}d_6$, 80 °C): δ 164.49, 153.70, 153.66, 153.11, 138.44, 133.05, 132.72, 130.49, 129.85, 129.66, 128.54, 127.35, 126.98, 125.22, 124.35, 124.34, 122.40, 119.85, 116.06, 81.24, 79.44, 67.81, 60.01, 28.35, 28.18, 16.46, 13.53. **HRMS (ESI)** m/z Calcd for $[\text{C}_{32}\text{H}_{39}\text{NNaO}_6, \text{M} + \text{Na}]^+$: 556.2669; Found: 556.2667.

Optical Rotation: $[\alpha]_D^{25} + 4.0$ ($c = 1.0$, CH_2Cl_2). 6% ee (HPLC condition: Chiralpak ID column, n -Hexane/ i -PrOH = 95:5, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 5.46$ min for major isomer, $t_R = 6.18$ min for minor isomer).

Supplementary Figure 35. HPLC Trace of Product 4p.



Recovered 1q




Syrup. $^1\text{H NMR}$ (400 MHz, CD_2Cl_2): δ 7.93 (dd, $J = 9.1, 0.8$ Hz, 1H), 7.84 – 7.78 (m, 1H), 7.36 (d, $J = 9.1$ Hz, 1H), 7.34 – 7.32 (m, 1H), 7.32 – 7.25 (m, 2H), 7.10 – 7.05 (m, 1H), 5.64 (br, 1H), 3.79 (s, 3H), 3.67 (s, 3H), 2.49 (s, 3H), 2.32 (s, 3H), 1.70 (s, 3H). $^{13}\text{C NMR}$ (75 MHz, CD_2Cl_2): δ 154.66, 154.10, 132.73, 131.70, 131.40, 131.05, 130.73, 129.22, 128.35, 127.42, 126.93, 124.00, 123.51, 121.22, 117.39, 113.08, 59.76, 56.05, 39.03, 16.09, 13.05. **HRMS (ESI)** m/z Calcd for $[\text{C}_{21}\text{H}_{23}\text{NNaO}_4\text{S}, \text{M} + \text{Na}]^+$: 408.1240; Found: 408.1242.


Optical Rotation: $[\alpha]_D^{25} + 2.4$ ($c = 0.5$, CHCl_3). 13% ee (HPLC condition: Chiralpak ID column,

n-Hexane/*i*-PrOH = 80:20, flow rate = 1.0 mL/min, wavelength = 254 nm, t_R = 11.19 min for major isomer, t_R = 12.56 min for minor isomer).

Supplementary Figure 36. HPLC Trace of Recovered 1q.




Product 4q



Syrup. $^1\text{H NMR}$ (500 MHz, DMSO- d_6 , 80 °C): δ 8.03 (d, J = 9.1 Hz, 1H), 7.95 – 7.88 (m, 1H), 7.54 (d, J = 9.0 Hz, 1H), 7.37 – 7.27 (m, 2H), 7.16 (s, 1H), 7.13 (d, J = 8.5 Hz, 1H), 5.94 (s, 1H), 5.45 (s, 1H), 4.00 (d, J = 16.8 Hz, 1H), 3.87 – 3.78 (m, 4H), 3.74 (s, 3H), 2.42 (s, 3H), 2.36 (s, 3H), 1.70 (s, 3H), 1.40 (s, 9H). $^{13}\text{C NMR}$ (125MHz, DMSO- d_6 , 80 °C): δ 165.32 , 156.76 , 154.19 , 137.67 , 135.95 , 135.34 , 133.40 , 131.96 , 131.93 , 130.26 , 130.14 , 129.07 , 128.28 , 126.89 , 126.76 , 125.15 , 123.93 , 120.58 , 114.04 , 80.98 , 60.06 , 56.26 , 50.43 , 40.71 , 28.13 , 16.24 , 13.42 . **HRMS (ESI)** m/z Calcd for $[\text{C}_{29}\text{H}_{35}\text{NNaO}_6\text{S}, \text{M} + \text{Na}]^+$: 548.2077; Found: 548.2075.


Optical Rotation: $[\alpha]_D^{25} - 3.4$ ($c = 0.5$, CH_2Cl_2). 18% ee (HPLC condition: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 80:20, flow rate = 1.0 mL/min, wavelength = 254 nm, t_R = 6.08 min for minor isomer, t_R = 7.43 min for major isomer).

Supplementary Figure 37. HPLC Trace of Product 4q.



Derivatization to access more NOBINs analogs and application to ATH:

Deallylation followed by kinetic resolution to access (*S*)-1b




The deallylation step followed a literature procedure.^[6] To a solution of (*S*)-**4b** (0.10 mmol) and NiCl₂(dppp) (5 mol %, 0.005 mmol) in toluene (1.0 mL) was added a 1M solution of diisobutylaluminum hydride in toluene (1.0 mL, 1.0 mmol) at 0 °C, and the reaction mixture was stirred for 3 h at 24 °C. The mixture was quenched with 1 M aqueous NaOH (1.0 mL), and the mixture was diluted with water (20 mL). The solution was extracted with ethyl acetate (3 × 15 mL). The combined extracts were dried over Na₂SO₄, and the resulting crude material was purified by thin layer chromatography on silica gel (hexane/ethyl acetate = 3/1 as eluent) to give (*S*)-**1b** (95% yield).


The following kinetic resolution followed our standard procedure using (DHQ)₂PHAL as the catalyst. The unreacted (*S*)-**1b** was recovered in 40% yield with 97% ee.

Optical Rotation: [α]_D²⁵ = -12.0 (*c* = 0.5, CHCl₃). 97% ee (HPLC condition: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, *t*_R = 11.46 min for minor isomer, *t*_R = 12.64 min for major isomer).

Supplementary Figure 38. HPLC Trace of (*S*)-1b.



General procedure for Pd-catalyzed Suzuki cross coupling:





The mixture of (R)-1b (45 mg, 0.1 mmol), phenyl boronic acid (15 mg, 0.2 mmol), Pd(PPh₃)₄ (0.02 mmol.), K₃PO₄ (5.5 mg, 0.4 mmol) in toluene (0.6 mL), EtOH (0.2 mL) and H₂O (0.3 mL) was heated at 95 °C for 12 h under N₂ atmosphere. After cooling to room temperature, the reaction was quenched by adding H₂O. The crude mixture was extracted with EtOAc (3 × 20 mL) and the combined organic extracts were washed with brine, dried over Na₂SO₄, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, hexanes/EtOAc = 100:1 v/v) to give the desired product 5a as a white solid (36 mg, 82% yield).

MP: 206 – 207 °C. **¹H NMR** (500 MHz, CDCl₃): δ 7.94 (s, 1H), 7.93 – 7.90 (m, 1H), 7.68 – 7.64 (m, 2H), 7.57 – 7.53 (m, 3H), 7.50 – 7.46 (m, 1H), 7.45 – 7.39 (m, 2H), 7.18 – 7.14 (m, 1H), 5.90 (s, 1H), 5.34 (s, 1H), 3.80 (s, 3H), 2.77 (s, 3H), 2.46 (s, 3H), 1.96 (s, 3H). **¹³C NMR** (125 MHz, CDCl₃): δ 154.98, 148.32, 136.75, 132.94, 132.67, 132.07, 131.81, 131.07, 130.54, 129.41, 129.38, 128.98, 128.80, 128.23, 127.65, 124.60, 124.36, 123.18, 121.37, 114.95, 60.14, 39.52, 16.58, 13.42. **HRMS (ESI)** m/z Calcd for [C₂₆H₂₅NNaO₄S, M + Na]⁺: 470.1396; Found: 470.1392.

Optical Rotation: [α]_D²⁵ + 8.0 (c = 0.3, CHCl₃). 98% ee (HPLC condition: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 92:8, flow rate = 1.0 mL/min, wavelength = 254 nm, *t*_R = 15.13 min for major isomer, *t*_R = 17.36 min for minor isomer).

Supplementary Figure 39. HPLC Trace of 5a.







The same procedure was followed to yield **5b** as an oil. ¹H NMR (500 MHz, CDCl₃): δ 7.97 (d, *J* = 8.5 Hz, 1H), 7.94 (d, *J* = 9.0 Hz, 1H), 7.66 (dd, *J* = 8.5, 1.8 Hz, 1H), 7.55 – 7.50 (m, 3H), 7.44 (dd, *J* = 8.4, 6.8 Hz, 2H), 7.37 (t, *J* = 7.3 Hz, 1H), 7.31 (d, *J* = 8.8 Hz, 1H), 7.28 (d, *J* = 6.6 Hz, 1H), 5.85 (s, 1H), 5.15 (s, 1H), 3.81 (s, 3H), 2.75 (s, 3H), 2.46 (s, 3H), 1.96 (s, 3H). ¹³C NMR (125 MHz, CDCl₃): δ 155.12, 151.35, 140.89, 140.66, 133.46, 132.98, 132.69, 132.10, 130.94, 129.32, 128.83, 128.58, 127.60, 127.45, 124.13, 123.31, 121.73, 120.95, 117.72, 114.36, 60.17, 39.70, 16.62, 13.40. HRMS (ESI) *m/z* Calcd for [C₂₆H₂₅NNaO₄S, M + Na]⁺: 470.1396; Found: 470.1398.

Optical Rotation: [α]_D²⁵ + 60.0 (*c* = 0.4, CHCl₃). 97% ee (HPLC condition: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, *t*_R = 10.05 min for major isomer, *t*_R = 19.54 min for minor isomer).


Supplementary Figure 40. HPLC Trace of 5b.



Access to free amino phenols and derivatization:





The synthesis of **6a** followed our previous procedure^[2] and the cross coupling step used the procedure shown in 5.2.



6a: Brown solid. **MP:** 176 - 177 °C. **¹H NMR** (400 MHz, DMSO-*d*₆): δ 8.33 (s, 1H), 7.92 – 7.86 (m, 1H), 7.44 – 7.33 (m, 2H), 7.03 – 6.95 (m, 1H), 6.87 (s, 1H), 3.67 (s, 3H), 2.31 (s, 3H), 1.70 (s, 3H). **¹³C NMR** (125 MHz, DMSO-*d*₆): δ 152.84, 149.32, 134.50, 132.62, 132.55, 131.80, 131.42, 129.68, 127.80, 127.54, 124.51, 124.08, 123.60, 119.46, 118.28, 114.55, 60.08, 16.46, 13.55. **HRMS (ESI)** *m/z* Calcd for [C₁₉H₁₈BrNNaO₂, M + Na]⁺: 394.0413; Found: 394.0416.

Optical Rotation: [α]_D²⁵ + 9.0 (*c* = 0.4, CHCl₃). 99% ee (HPLC condition: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, *t*_R = 8.57 min for minor isomer, *t*_R = 16.93 min for major isomer).


Supplementary Figure 41. HPLC Trace of 6a.




6b: Syrup. **¹H NMR** (500 MHz, CDCl₃): δ 7.92 (s, 1H), 7.89 (dd, *J* = 6.2, 3.3 Hz, 1H), 7.77 – 7.73 (m, 2H), 7.50 (t, *J* = 7.7 Hz, 2H), 7.45 – 7.37 (m, 3H), 7.33 (dt, *J* = 6.1, 3.5 Hz, 1H), 6.63 (s, 1H), 3.75 (s, 3H), 2.37 (s, 3H), 1.93 (s, 3H). **¹³C NMR** (125 MHz, CDCl₃): δ 150.13, 148.64, 141.64, 137.97, 132.55, 132.20, 132.11, 130.49, 130.09, 129.58, 129.38, 128.34, 128.27, 127.48, 126.87, 123.94, 123.90, 116.76, 116.42, 115.66, 60.26, 16.34, 13.15. **HRMS (ESI)** *m/z* Calcd for [C₂₅H₂₃NNaO₂, M + Na]⁺: 392.1621; Found: 392.1624.

Optical Rotation: [α]_D²⁵ + 40.0 (*c* = 0.2, CHCl₃). 99% ee (HPLC condition: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, *t*_R = 8.43 min for major isomer, *t*_R = 14.04 min for minor isomer).

Supplementary Figure 42. HPLC Trace of 6b.



Access to pyridine-containing amino alcohol 7 and application to ATH:





The synthesis of (*R*)-1-(6-amino-3-methoxy-2,4-dimethylphenyl)naphthalen-2-ol followed our previous procedure^[2]

(*R*)-1-(6-amino-3-methoxy-2,4-dimethylphenyl)naphthalen-2-ol (60 mg, 0.2 mmol) was mixed with Pyridine-2-carboxaldehyde (24 mg, 0.22 mmol) in dry toluene (1 mL). 140 mg 4 Å molecular sieves were added, and the solution was warmed up to 70 °C and kept for one day at this temperature. The solution was filtered and the solvent was removed under reduced pressure. The resulting light yellow solid was dissolved in EtOH (2 mL) and cooled to 0 °C. NaBH₄ (0.8 mmol) was added to the reaction flask. The reaction mixture was then left to stir at 24 °C for 4 h. The solvent was removed and the residue was treated with H₂O (5 mL) and extracted with ethyl acetate (10 mL x 3) and washed with brine (10 mL). The combined organic layers were dried with anhydrous Na₂SO₄ and the solvent was removed under reduced pressure. The residue was further purified by flash column chromatography (hexane/ethyl acetate = 2:1) to give **7** (38 mg, 50% yield). ¹H NMR (500 MHz, CD₂Cl₂) δ 8.49 (d, *J* = 4.6 Hz, 1H), 7.96 – 7.87 (m, 2H), 7.80 – 7.71 (m, 1H), 7.43 – 7.36 (m, 3H), 7.36 – 7.28 (m, 2H), 7.29 – 7.23 (m, 1H), 6.42 (s, 1H), 4.54 (d, *J* = 17.2 Hz, 1H), 4.38 (d, *J* = 17.2 Hz, 1H), 4.24 – 4.19 (m, 1H), 3.70 (s, 3H), 2.28 (s, 3H), 1.81 (s, 3H). ¹³C NMR (125 MHz, CD₂Cl₂) δ 158.59, 151.70, 149.44, 142.19, 133.36, 131.93, 131.78, 130.86, 129.82, 129.52, 128.16, 126.70, 124.08, 123.45, 122.31, 121.94, 118.66, 116.46, 111.30, 59.95, 48.18, 16.27, 12.91. **HRMS (ESI)** *m/z* Calcd for [C₂₅H₂₄N₂NaO₂, M + Na]⁺: 407.1730; Found: 407.1734.

Optical Rotation: [α]_D²⁵ - 36.0 (*c* = 1.0, CH₂Cl₂). 98% ee (HPLC condition: Chiralcel OD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, *t*_R = 7.71 min for major isomer, *t*_R = 11.85 min for minor isomer).


Supplementary Figure 43. HPLC Trace of 7.



The ligand **7** (4.7 μmol) was dissolved in 2-propanol (5.2 mL) under N_2 and a solution of KO^tBu in 2-propanol (0.95 mL of 0.01 mol/L) was added. $\text{Ru(PPh}_3)_3\text{Cl}_2$ (4.1 mg 4.3 μmol) dissolved in 2-propanol (2.5 mL), was added. The solution was stirred at room temperature for 1.5 h to accomplish the formation of the catalyst. Then, the reaction vessel was thermostated to 30 $^\circ\text{C}$. Addition of acetophenone (50 μL) afforded a substrate concentration of 0.05 mol/L. The reaction was started by adding another 0.43 mL of the 0.01 mol/L KO^tBu solution. After 15 h the reaction was stopped by addition of 0.1 mol/L solution of acetic acid in 2-propanol (0.15 mL). After removal the solvent, the crude residue was purified by column chromatography with hexanes/ethyl acetate (10:1 v/v) as eluent to afford the product **8**. $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 7.43 – 7.35 (m, 4H), 7.33 – 7.29 (m, 1H), 4.92 (qd, $J = 6.4, 3.1$ Hz, 1H), 2.04 – 1.96 (m, 1H), 1.53 (d, $J = 6.5$ Hz, 3H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3): δ 145.82, 128.50, 127.48, 125.39, 70.42, 25.16.

Optical Rotation: $[\alpha]^{25}_{\text{D}} = 36.0$ ($c = 1.0$, CHCl_3). The absolute configuration of **8** was assigned by comparing its specific rotation with that of the same compound reported in the literature.^[7] 93% ee (HPLC condition: Chiralcel OD-H column, n -Hexane/ i -PrOH = 98:2, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_{\text{R}} = 14.95$ min for major isomer, $t_{\text{R}} = 19.16$ min for minor isomer).

Supplementary Figure 44. HPLC Trace of **8**.




Supplementary Table 1. Optimization of the Reaction Conditions^a

entry	cat	solvent	T, (°C)	10ba, yield(%) ^b , ee (%) ^c
1	β -ICD	CH ₂ Cl ₂	24	99, -41
2	(DHQD) ₂ AQN	CH ₂ Cl ₂	24	90, -30
3	(DHQD) ₂ Pyr	CH ₂ Cl ₂	24	86, -50
4	(DHQD) ₂ PHAL	CH ₂ Cl ₂	24	92, -67
5	(DHQ) ₂ AQN	CH ₂ Cl ₂	24	91, 41
6	(DHQ) ₂ Pyr	CH ₂ Cl ₂	24	86, 72
7	(DHQ) ₂ PHAL	CH ₂ Cl ₂	24	96, 78
8	(DHQ) ₂ PHAL	THF	24	95, 72
9	(DHQ) ₂ PHAL	CH ₃ CN	24	95, 80
10	(DHQ) ₂ PHAL	EtOAc	24	92, 73
11	(DHQ) ₂ PHAL	CHCl ₃	24	91, 74
12	(DHQ) ₂ PHAL	toluene	24	81, 51
13 ^d	(DHQ) ₂ PHAL	CH ₃ CN	-20	90, 87
14 ^d	(DHQ)₂PHAL	1:1 CH₂Cl₂/CH₃CN	-20	85, 92
15 ^d	(DHQD) ₂ PHAL	1:1 CH ₂ Cl ₂ /CH ₃ CN	-20	86, -87


^a Unless noted otherwise, the reactions were performed with **9b** (0.04 mmol, 1.0 equiv.), **2a** (1.5 equiv.), catalyst (10 mol%) in solvent (0.5 mL) at 24 °C for 18 h. ^b isolated yield. ^c Determined by chiral HPLC. ^d 96 h instead of 18 h.

Representative procedure for synthesis of 10:



To a 4 mL vial containing **9** (0.04 mmol) and (DHQ)₂PHAL (3.0 mg, 10 mol%) were added CH₂Cl₂ (0.25 mL) and CH₃CN (0.25 mL). The reaction mixture was allowed to stir for 10 minutes at -20 °C. Then MBH carbonate (12 μ L) was added. Once the starting material **9** consumed completely. The volatiles were removed *in vacuo* at 24 °C and the residue was purified by silica gel column chromatography with hexanes/ethyl acetate (10:1 v/v) as the eluent to afford the product **10**.



Characterization of compounds:



9aa. Syrup. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.55 (d, $J = 8.3$ Hz, 2H), 7.48 (dd, $J = 8.2, 1.6$ Hz, 1H), 7.27 – 7.21 (m, 2H), 7.16 (td, $J = 8.0, 1.5$ Hz, 1H), 6.88 (td, $J = 8.0, 7.1$, 1H), 6.39 (dd, $J = 8.0, 1.5$ Hz, 1H), 6.14 (d, $J = 1.2$ Hz, 1H), 5.45 (d, $J = 1.1$ Hz, 1H), 4.63 (dd, $J = 13.6, 0.8$ Hz, 1H), 4.03 (dd, $J = 13.6, 0.7$ Hz, 1H), 3.96 – 3.84 (m, 2H), 2.38 (s, 3H), 1.41 (s, 9H), 1.04 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 166.08, 150.73, 143.61, 136.64, 135.55, 135.17, 131.58, 130.80, 129.74, 129.33, 128.94, 128.32, 125.66, 61.01, 52.29, 36.91, 33.01, 21.58, 13.94. **HRMS (ESI)** m/z Calcd for $[\text{C}_{23}\text{H}_{29}\text{NNaO}_4\text{S}, \text{M} + \text{Na}]^+$: 438.1709; Found: 438.1706.

Optical Rotation: $[\alpha]_D^{25} - 20.0$ ($c = 1.0$, CHCl_3). 71% ee (HPLC condition: Chiralpak AD-H column, n -Hexane/ i -PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 7.35$ min for minor isomer, $t_R = 9.10$ min for major isomer).

Supplementary Figure 45. HPLC Trace of 9aa.





9ba. White solid. **MP:** 122-124 °C. $^1\text{H NMR}$ (500 MHz, CD_2Cl_2) δ 7.82 – 7.76 (m, 2H), 7.59 (d, $J = 1.9$ Hz, 1H), 7.40 – 7.34 (m, 2H), 7.06 (d, $J = 1.2$ Hz, 1H), 6.31 (s, 1H), 5.82 (s, 1H), 4.61 (d, $J = 14.3$ Hz, 1H), 4.57 (d, $J = 14.1$ Hz, 1H), 4.13 – 3.95 (m, 2H), 2.49 (s, 3H), 2.30 (s, 3H), 2.18 (s, 3H), 1.17 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C NMR}$ (125 MHz, CD_2Cl_2) δ 166.01, 143.76, 141.94, 140.00, 139.06, 138.33, 137.35, 135.98, 132.22, 131.49, 129.52, 128.23, 100.97, 60.97, 49.97, 21.43, 20.18, 13.78. **HRMS (ESI)** m/z Calcd for $[\text{C}_{21}\text{H}_{24}\text{INNaO}_4\text{S}, \text{M} + \text{Na}]^+$: 536.0363; Found: 536.0367.

Optical Rotation: $[\alpha]_D^{25} - 30.0$ ($c = 1.0$, CHCl_3). 92% ee (HPLC condition: Chiralpak AD-H

column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, t_R = 10.96 min for minor isomer, t_R = 11.74 min for major isomer).


Supplementary Figure 46. HPLC Trace of 9ba.




9bb. Syrup. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.66 (d, J = 8.3 Hz, 2H), 7.42 (dt, J = 2.1, 0.7 Hz, 1H), 7.24 – 7.18 (m, 2H), 6.94 – 6.90 (m, 1H), 6.18 (d, J = 1.4 Hz, 1H), 5.73 (d, J = 1.4 Hz, 1H), 4.50 (dd, J = 14.2, 0.6 Hz, 1H), 4.40 (d, J = 14.3 Hz, 1H), 2.35 (s, 3H), 2.16 (s, 3H), 2.15 (s, 3H), 1.24 (s, 9H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 165.18, 143.41, 142.44, 139.83, 139.07, 138.57, 137.30, 132.29, 131.27, 129.46, 128.32, 100.37, 81.01, 49.72, 27.74, 21.59, 20.60, 20.33. **HRMS (ESI)** m/z Calcd for $[\text{C}_{23}\text{H}_{28}\text{INaO}_4\text{S}, \text{M} + \text{Na}]^+$: 564.0676; Found: 564.0679.

Optical Rotation: $[\alpha]_D^{25}$ - 30.0 (c = 1.0, CHCl_3). 92% ee (HPLC condition: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, t_R = 8.12 min for major isomer, t_R = 9.50 min for minor isomer).

Supplementary Figure 47. HPLC Trace of 9bb.





Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %	Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.262	BB	0.2232	309.25885	21.20106	50.4792	1	8.122	VB	0.2235	3015.02222	206.32355	95.9936
2	9.648	BB	0.2500	303.38675	18.62873	49.5208	2	9.503	BB	0.2434	125.83624	8.04706	4.0064



9bc. Syrup. $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.78 (d, $J = 8.3$ Hz, 2H), 7.53 (d, $J = 2.0$ Hz, 1H), 7.37 – 7.29 (m, 2H), 7.01 (d, $J = 2.0$ Hz, 1H), 6.30 (d, $J = 1.3$ Hz, 1H), 5.79 (d, $J = 1.2$ Hz, 1H), 4.64 – 4.57 (m, 1H), 4.55 (d, $J = 14.2$ Hz, 1H), 3.59 (s, 3H), 2.45 (s, 3H), 2.25 (s, 3H), 2.20 (s, 3H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 166.56, 143.53, 141.96, 139.85, 139.10, 138.30, 137.23, 135.53, 132.28, 131.92, 129.45, 128.38, 100.81, 51.94, 50.13, 21.60, 20.36, 20.31. **HRMS (ESI)** m/z Calcd for $[\text{C}_{20}\text{H}_{22}\text{INNaO}_4\text{S}, \text{M} + \text{Na}]^+$: 522.0206; Found: 522.0202.

Optical Rotation: $[\alpha]_D^{25} - 30.0$ ($c = 1.0$, CHCl_3). 93% ee (HPLC condition: Chiralpak AD-H column, n -Hexane/ i -PrOH = 95:5, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 29.35$ min for minor isomer, $t_R = 34.78$ min for major isomer).

Supplementary Figure 48. HPLC Trace of **9bc**.





9bd. Syrup. $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.77 (d, $J = 8.4$ Hz, 2H), 7.52 (d, $J = 2.0$ Hz, 1H), 7.31 (d, $J = 8.1$ Hz, 2H), 7.01 (d, $J = 2.0$ Hz, 1H), 6.33 (d, $J = 1.3$ Hz, 1H), 5.87 (d, $J = 1.3$ Hz, 1H), 4.61 (d, $J = 14.2$ Hz, 1H), 4.54 (d, $J = 14.3$ Hz, 1H), 4.02 (dt, $J = 10.7, 6.8$ Hz, 1H), 3.94 (dt, $J = 10.8, 6.6$ Hz, 1H), 2.45 (s, 3H), 2.25 (s, 3H), 2.21 (s, 3H), 1.54 – 1.45 (m, 2H), 1.38 – 1.26 (m, 2H), 0.91 (t, $J = 7.4$ Hz, 3H).

^{13}C NMR (125 MHz, CDCl_3) δ 166.20 , 143.49 , 142.08 , 139.81 , 139.10 , 138.39 , 137.35 , 135.97 , 132.26 , 131.70 , 129.47 , 128.34 , 100.67 , 64.88 , 50.04 , 30.38 , 21.60 , 20.42 , 20.36 , 19.11 , 13.71 .
HRMS (ESI) m/z Calcd for $[\text{C}_{23}\text{H}_{28}\text{INNaO}_4\text{S}, \text{M} + \text{Na}]^+$: 564.0676; Found: 564.0673.

Optical Rotation: $[\alpha]_D^{25}$ - 25.0 ($c = 1.0$, CHCl_3). 93% ee (HPLC condition: Chiralpak OD-H column, n -Hexane/ i -PrOH = 99:1, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 15.72$ min for major isomer, $t_R = 17.82$ min for minor isomer).



Supplementary Figure 49. HPLC Trace of **9bd**.



9be. Syrup. ^1H NMR (500 MHz, CDCl_3) δ 7.79 – 7.74 (m, 2H), 7.48 (d, $J = 2.0$ Hz, 1H), 7.40 – 7.34 (m, 3H), 7.31 – 7.26 (m, 4H), 6.96 (d, $J = 1.9$ Hz, 1H), 6.38 (d, $J = 1.2$ Hz, 1H), 5.88 (d, $J = 1.1$ Hz, 1H), 5.10 (d, $J = 12.3$ Hz, 1H), 5.00 (d, $J = 12.4$ Hz, 1H), 4.62 (d, $J = 14.3$ Hz, 1H), 4.57 (d, $J = 14.3$ Hz, 1H), 2.45 (s, 3H), 2.23 (s, 3H), 2.15 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 165.92 , 143.49 , 141.93 , 139.80 , 139.10 , 138.31 , 137.32 , 135.73 , 135.58 , 132.27 , 132.20 , 129.46 , 128.42 , 128.38 , 128.24 , 128.19 , 100.80 , 66.72 , 50.13 , 21.61 , 20.40 , 20.36 . **HRMS (ESI)** m/z Calcd for $[\text{C}_{26}\text{H}_{26}\text{INNaO}_4\text{S}, \text{M} + \text{Na}]^+$: 598.0519; Found: 598.0514.

Optical Rotation: $[\alpha]_D^{25}$ - 35.0 ($c = 1.0$, CHCl_3). 92% ee (HPLC condition: Chiralpak AD-H column, n -Hexane/ i -PrOH = 95:5, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 28.42$ min for minor isomer, $t_R = 31.29$ min for major isomer).


Supplementary Figure 50. HPLC Trace of 9be.




9ca. White solid. **MP:** 132-134 °C. $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.77 (d, $J = 8.3$ Hz, 2H), 7.69 (d, $J = 2.5$ Hz, 1H), 7.35 – 7.31 (m, 2H), 7.24 – 7.18 (m, 1H), 6.35 (d, $J = 1.2$ Hz, 1H), 5.88 (d, $J = 1.2$ Hz, 1H), 4.60 (d, $J = 14.2$ Hz, 1H), 4.53 (d, $J = 14.3$ Hz, 1H), 4.09 (dq, $J = 10.8, 7.1$ Hz, 1H), 4.02 (dq, $J = 10.8, 7.1$ Hz, 1H), 2.46 (s, 3H), 2.24 (s, 3H), 1.17 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 166.00, 143.88, 143.85, 138.99, 138.10, 137.77, 135.72, 134.36, 132.00, 131.23, 129.61, 128.31, 100.98, 61.10, 50.02, 21.62, 20.55, 13.94. **HRMS (ESI)** m/z Calcd for $[\text{C}_{20}\text{H}_{21}\text{ClINNaO}_4\text{S}, \text{M} + \text{Na}]^+$: 555.9816; Found: 555.9818.

Optical Rotation: $[\alpha]_D^{25} - 40.0$ ($c = 1.0$, CHCl_3). 91% ee (HPLC condition: Chiralpak OD-H column, n -Hexane/ i -PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 7.48$ min for major isomer, $t_R = 8.62$ min for minor isomer).

Supplementary Figure 51. HPLC Trace of 9ca.







9da. White solid. **MP:** 128-129 °C. **¹H NMR** (500 MHz, CDCl₃) δ 7.84 (d, *J* = 2.3 Hz, 1H), 7.76 (d, *J* = 8.2 Hz, 2H), 7.37 (d, *J* = 2.3 Hz, 1H), 7.33 (d, *J* = 8.1 Hz, 2H), 6.35 (d, *J* = 1.1 Hz, 1H), 5.88 (d, *J* = 1.1 Hz, 1H), 4.59 (d, *J* = 14.3 Hz, 1H), 4.52 (d, *J* = 14.3 Hz, 1H), 4.14 – 3.97 (m, 2H), 2.46 (s, 3H), 2.24 (s, 3H), 1.22 – 1.10 (m, 3H). **¹³C NMR** (125 MHz, CDCl₃) δ 165.99 , 144.33 , 143.86 , 140.47 , 139.49 , 138.08 , 135.70 , 134.20 , 132.01 , 129.61 , 128.31 , 122.58 , 101.41 , 61.11 , 49.97 , 21.62 , 20.46 , 13.94 . **HRMS (ESI)** *m/z* Calcd for [C₂₀H₂₁BrINNaO₄S, M + Na]⁺: 555.9816; Found: 555.9818.

Optical Rotation: [α]_D²⁵ - 25.0 (*c* = 0.5, CHCl₃). 91% ee (HPLC condition: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 95:5, flow rate = 1.0 mL/min, wavelength = 254 nm, *t*_R = 10.13 min for major isomer, *t*_R = 12.07 min for minor isomer).

Supplementary Figure 52. HPLC Trace of **9da**.





9ea. Syrup. **¹H NMR** (500 MHz, CDCl₃) δ 8.03 (d, *J* = 2.0 Hz, 1H), 7.79 – 7.72 (m, 2H), 7.55 (d, *J* = 2.0 Hz, 1H), 7.33 (d, *J* = 8.1 Hz, 2H), 6.35 (d, *J* = 1.2 Hz, 1H), 5.87 (d, *J* = 1.1 Hz, 1H), 4.59 (d, *J* = 14.2 Hz, 1H), 4.52 (d, *J* = 14.3 Hz, 1H), 4.14 – 3.97 (m, 2H), 2.46 (s, 3H), 2.21 (s, 3H), 1.16 (t, *J* = 7.1 Hz, 3H). **¹³C NMR** (125 MHz, CDCl₃) δ 165.99 , 146.09 , 144.66 , 143.85 , 140.25 , 138.08 , 135.70 , 132.00 , 129.61 , 128.31 , 101.88 , 94.83 , 61.11 , 49.95 , 21.63 , 20.22 , 13.94 . **HRMS (ESI)** *m/z* Calcd for [C₂₀H₂₁I₂NNaO₄S, M + Na]⁺: 647.9173; Found: 647.9177.

Optical Rotation: [α]_D²⁵ - 15.0 (*c* = 1.0, CHCl₃). 89% ee (HPLC condition: Chiralpak AD-H

column, *n*-Hexane/*i*-PrOH = 98:2, flow rate = 1.0 mL/min, wavelength = 254 nm, t_R = 33.30 min for major isomer, t_R = 37.02 min for minor isomer).


Supplementary Figure 53. HPLC Trace of 9ea.




9fa. Syrup. $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.03 (d, J = 2.1 Hz, 1H), 7.76 (d, J = 8.3 Hz, 2H), 7.61 (d, J = 2.1 Hz, 1H), 7.33 (d, J = 8.1 Hz, 2H), 6.35 (d, J = 1.1 Hz, 1H), 5.85 (d, J = 1.1 Hz, 1H), 4.57 (d, J = 14.3 Hz, 1H), 4.52 (d, J = 14.3 Hz, 1H), 4.14 – 3.96 (m, 2H), 2.65 (dq, J = 15.1, 7.5 Hz, 1H), 2.53 – 2.47 (m, 1H), 2.46 (s, 3H), 1.16 (t, J = 7.5 Hz, 6H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 165.90, 150.25, 145.91, 143.81, 139.47, 138.34, 138.05, 135.53, 132.13, 129.56, 128.37, 101.81, 95.28, 61.09, 49.98, 25.19, 21.62, 14.27, 13.94. **HRMS (ESI)** m/z Calcd for $[\text{C}_{21}\text{H}_{23}\text{I}_2\text{NNaO}_4\text{S}, \text{M} + \text{Na}]^+$: 661.9329; Found: 661.9324.

Optical Rotation: $[\alpha]_D^{25} + 20.0$ (c = 1.0, CHCl_3). 95% ee (HPLC condition: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 98:2, flow rate = 1.0 mL/min, wavelength = 254 nm, t_R = 23.34 min for major isomer, t_R = 27.21 for minor isomer).

Supplementary Figure 54. HPLC Trace of 9fa.





Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %	Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	23.839	BB	0.6063	400.01193	10.05135	50.0716	1	23.348	BB	0.6071	583.21448	14.72318	97.2546
2	27.634	BB	0.7050	398.86850	8.55420	49.9284	2	27.219	MM	0.7520	16.46364	3.64873e-1	2.7454



9ga. Syrup. $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.04 (d, $J = 2.0$ Hz, 1H), 7.77 (d, $J = 8.4$ Hz, 2H), 7.60 (d, $J = 2.0$ Hz, 1H), 7.33 (d, $J = 8.0$ Hz, 2H), 6.35 (d, $J = 1.2$ Hz, 1H), 5.84 (d, $J = 1.3$ Hz, 1H), 4.55 (s, 2H), 4.12 – 3.99 (m, 2H), 2.50 (ddd, $J = 15.0, 11.7, 5.2$ Hz, 1H), 2.46 (s, 3H), 2.36 (ddd, $J = 15.0, 11.7, 5.1$ Hz, 1H), 1.68 – 1.61 (m, 1H), 1.52 – 1.41 (m, 1H), 1.17 (t, $J = 7.1$ Hz, 3H), 0.91 (t, $J = 7.3$ Hz, 4H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 165.91, 148.86, 145.94, 143.81, 139.51, 138.67, 138.06, 135.49, 132.12, 129.55, 128.37, 102.32, 95.20, 61.09, 50.03, 34.24, 23.43, 21.60, 14.16, 13.96. **HRMS (ESI)** m/z Calcd for $[\text{C}_{22}\text{H}_{25}\text{I}_2\text{NNaO}_4\text{S}, \text{M} + \text{Na}]^+$: 675.9486; Found: 675.9488.

Optical Rotation: $[\alpha]_D^{25} - 15.0$ ($c = 1.0$, CHCl_3). 95% ee (HPLC condition: Chiralpak AD-H column, n -Hexane/ i -PrOH = 95:5, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 14.46$ min for major isomer, $t_R = 15.78$ for minor isomer).

Supplementary Figure 55. HPLC Trace of **9ga**.





9ha. Syrup. $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.02 (d, $J = 2.0$ Hz, 1H), 7.82 (d, $J = 8.1$ Hz, 2H), 7.60 (d, $J = 2.0$ Hz, 1H), 7.33 (d, $J = 8.0$ Hz, 2H), 6.38 (d, $J = 1.2$ Hz, 1H), 5.81 (s, 1H), 4.63 (d, $J = 14.3$ Hz, 1H), 4.48 (d, $J = 14.4$ Hz, 1H), 4.07 (p, $J = 7.2$ Hz, 2H), 3.18 (p, $J = 6.8$ Hz, 1H), 2.45 (s, 3H), 1.26 (d, $J = 6.6$

Hz, 3H), 1.16 (t, $J = 7.1$ Hz, 3H), 1.11 (d, $J = 6.8$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 165.83, 155.28, 145.94, 143.84, 138.49, 137.96, 137.09, 135.33, 132.50, 129.48, 128.68, 101.94, 95.62, 61.09, 49.78, 29.98, 24.92, 24.38, 21.63, 13.98. HRMS (ESI) m/z Calcd for $[\text{C}_{22}\text{H}_{25}\text{I}_2\text{NNaO}_4\text{S}, \text{M} + \text{Na}]^+$: 675.9486; Found: 675.9482.

Optical Rotation: $[\alpha]_D^{25} + 15.0$ ($c = 1.0$, CHCl_3). 92% ee (HPLC condition: Chiralpak AD-H column, n -Hexane/ i -PrOH = 98:2, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 16.18$ min for major isomer, $t_R = 21.63$ for minor isomer).



Supplementary Figure 56. HPLC Trace of **9ha**.



9a. Syrup. ^1H NMR (500 MHz, CDCl_3) δ 7.84 (d, $J = 2.3$ Hz, 1H), 7.79 – 7.75 (m, 2H), 7.43 (d, $J = 2.3$ Hz, 1H), 7.33 (d, $J = 8.0$ Hz, 2H), 6.36 (d, $J = 1.2$ Hz, 1H), 5.85 (d, $J = 1.0$ Hz, 1H), 4.56 (s, 1H), 4.53 (d, $J = 14.3$ Hz, 1H), 4.14 – 3.96 (m, 2H), 2.68 (dq, $J = 15.1, 7.5$ Hz, 1H), 2.52 (dq, $J = 15.2, 7.6$ Hz, 1H), 2.46 (s, 3H), 1.17 (td, $J = 7.4, 3.5$ Hz, 7H). ^{13}C NMR (125 MHz, CDCl_3) δ 165.89, 149.94, 143.82, 140.30, 138.74, 138.06, 135.55, 132.23, 132.13, 129.57, 128.37, 123.04, 101.34, 61.08, 50.00, 25.40, 21.62, 14.22, 13.94. HRMS (ESI) m/z Calcd for $[\text{C}_{21}\text{H}_{23}\text{BrINNaO}_4\text{S}, \text{M} + \text{Na}]^+$: 613.9468; Found: 613.9464.

Optical Rotation: $[\alpha]_D^{25} - 15.0$ ($c = 1.0$, CHCl_3). 95% ee (HPLC condition: Chiralpak AD-H column, n -Hexane/ i -PrOH = 98:2, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 21.47$ min for major isomer, $t_R = 23.61$ for minor isomer).


Supplementary Figure 57. HPLC Trace of **9ja**.




9ja. Syrup. $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.75 (d, $J = 8.3$ Hz, 2H), 7.30 (d, $J = 8.1$ Hz, 2H), 7.20 (d, $J = 2.0$ Hz, 1H), 7.03 – 6.96 (m, 1H), 6.29 (t, $J = 0.9$ Hz, 1H), 5.80 (d, $J = 1.1$ Hz, 1H), 4.64 (d, $J = 14.1$ Hz, 1H), 4.47 (d, $J = 14.1$ Hz, 1H), 4.18 – 3.95 (m, 2H), 2.45 (s, 3H), 2.28 (s, 4H), 2.27 (s, 3H), 1.17 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 166.05, 143.41, 142.82, 139.67, 137.96, 135.93, 133.84, 132.10, 131.30, 131.29, 129.38, 128.14, 124.59, 60.96, 49.73, 21.58, 20.65, 20.00, 13.91. **HRMS (ESI)** m/z Calcd for $[\text{C}_{21}\text{H}_{24}\text{BrNNaO}_4\text{S}, \text{M} + \text{Na}]^+$: 488.0501; Found: 488.0505.

Optical Rotation: $[\alpha]_D^{25} +20.0$ ($c = 1.0$, CHCl_3). 93% ee (HPLC condition: Chiralpak OD-H column, n -Hexane/ i -PrOH = 95:5, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 9.72$ min for major isomer, $t_R = 10.86$ for minor isomer).

Supplementary Figure 58. HPLC Trace of **9ja**.







9ka. Syrup. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.72 (d, $J = 8.3$ Hz, 2H), 7.29 (d, $J = 8.2$ Hz, 2H), 6.98 (d, $J = 2.0$ Hz, 1H), 6.96 (d, $J = 2.0$ Hz, 1H), 6.27 (d, $J = 1.2$ Hz, 1H), 5.77 (d, $J = 1.1$ Hz, 1H), 4.66 (dd, $J = 14.1, 0.8$ Hz, 1H), 4.39 (d, $J = 14.1$ Hz, 1H), 4.16 – 3.98 (m, 2H), 2.45 (s, 3H), 2.28 (s, 3H), 2.28 (s, 3H), 1.18 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 165.99, 143.38, 142.65, 139.40, 137.72, 135.92, 134.29, 132.31, 131.01, 130.63, 129.37, 128.64, 127.99, 60.95, 49.72, 21.57, 20.78, 19.65, 13.92. **HRMS (ESI)** m/z Calcd for $[\text{C}_{21}\text{H}_{24}\text{ClNNaO}_4\text{S}, \text{M} + \text{Na}]^+$: 444.1007; Found: 444.1004.

Optical Rotation: $[\alpha]_D^{25} +35.0$ ($c = 1.0$, CHCl_3). 87% ee (HPLC condition: Chiralpak OD-H column, n -Hexane/ i -PrOH = 98:2, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 14.42$ min for major isomer, $t_R = 15.92$ for minor isomer).



Supplementary Figure 59. HPLC Trace of **9ka**.



9la. Syrup. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.48 (d, $J = 2.0$ Hz, 1H), 6.96 (d, $J = 2.0$ Hz, 1H), 6.16 (d, $J = 1.1$ Hz, 1H), 5.38 (d, $J = 1.1$ Hz, 1H), 4.64 (d, $J = 14.1$ Hz, 1H), 4.19 – 4.05 (m, 3H), 3.33 (s, 3H), 2.31 (s, 3H), 2.17 (s, 3H), 1.19 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 166.28, 140.94, 140.13, 138.62, 137.23, 135.17, 132.60, 131.79, 103.07, 61.27, 50.46, 42.85, 20.38, 20.14, 14.14. **HRMS (ESI)** m/z Calcd for $[\text{C}_{15}\text{H}_{20}\text{INNaO}_4\text{S}, \text{M} + \text{Na}]^+$: 460.0050; Found: 460.0054.

Optical Rotation: $[\alpha]_D^{25} - 40.0$ ($c = 1.0$, CHCl_3). 91% ee (HPLC condition: Chiralpak AD-H column, n -Hexane/ i -PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 11.16$ min for major isomer, $t_R = 13.97$ min for minor isomer).


Supplementary Figure 60. HPLC Trace of 9la.




9ma. Syrup. $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.89 (dd, $J = 8.3, 1.4$ Hz, 2H), 7.63 – 7.58 (m, 1H), 7.55 – 7.50 (m, 3H), 7.02 (d, $J = 2.0$ Hz, 1H), 6.33 (d, $J = 1.2$ Hz, 1H), 5.84 (d, $J = 1.1$ Hz, 1H), 4.65 (d, $J = 14.2$ Hz, 1H), 4.57 (d, $J = 14.1$ Hz, 1H), 4.09 (dq, $J = 10.7, 7.2$ Hz, 1H), 4.01 (dq, $J = 10.7, 7.0$ Hz, 1H), 2.26 (s, 3H), 2.21 (s, 3H), 1.16 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 166.09, 142.15, 141.26, 139.93, 139.14, 137.10, 135.84, 132.77, 132.29, 131.84, 128.91, 128.28, 100.44, 61.00, 50.08, 20.37, 20.35, 13.93. **HRMS (ESI)** m/z Calcd for $[\text{C}_{20}\text{H}_{22}\text{INNaO}_4\text{S}, \text{M} + \text{Na}]^+$: 522.0206; Found: 522.0202.

Optical Rotation: $[\alpha]_D^{25} - 40.0$ ($c = 1.0$, CHCl_3). 90% ee (HPLC condition: Chiralpak OD-H column, n -Hexane/ i -PrOH = 98:2, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 16.48$ min for major isomer, $t_R = 18.65$ for minor isomer).

Supplementary Figure 61. HPLC Trace of 9ma.







9na. Syrup. $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.86 – 7.80 (m, 2H), 7.53 (d, $J = 2.0$ Hz, 1H), 7.05 – 7.01 (m, 1H), 6.98 (d, $J = 8.9$ Hz, 2H), 6.31 (d, $J = 1.2$ Hz, 1H), 5.82 (d, $J = 1.1$ Hz, 1H), 4.60 (d, $J = 14.3$ Hz, 1H), 4.54 (d, $J = 14.2$ Hz, 1H), 4.13 – 4.06 (m, 1H), 4.06 – 3.98 (m, 1H), 3.89 (s, 3H), 2.25 (s, 3H), 2.23 (s, 3H), 1.16 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 166.15, 163.07, 142.13, 139.82, 139.08, 137.40, 135.98, 133.22, 132.28, 131.60, 130.42, 113.96, 100.54, 60.97, 55.61, 49.99, 20.42, 20.35, 13.92. **HRMS (ESI)** m/z Calcd for $[\text{C}_{21}\text{H}_{24}\text{INNaO}_5\text{S}, \text{M} + \text{Na}]^+$: 552.0312; Found: 552.0316.

Optical Rotation: $[\alpha]_D^{25} - 28.0$ ($c = 1.0$, CHCl_3). 93% ee (HPLC condition: Chiralpak IC column, n -Hexane/ i -PrOH = 80:20, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 16.48$ min for major isomer, $t_R = 18.65$ for minor isomer).

Supplementary Figure 62. HPLC Trace of **9na**.





9oa. Syrup. $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.86 – 7.81 (m, 2H), 7.53 (t, $J = 1.4$ Hz, 1H), 7.51 – 7.48 (m, 2H), 7.04 – 7.02 (m, 1H), 6.32 (d, $J = 1.1$ Hz, 1H), 5.80 (s, 1H), 4.63 (d, $J = 14.2$ Hz, 1H), 4.55 (d, $J = 14.2$ Hz, 1H), 4.14 – 4.07 (m, 1H), 4.06 – 3.97 (m, 1H), 2.26 (s, 3H), 2.24 (s, 3H), 1.17 (t, $J = 7.1$, 3H). $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 166.01, 142.25, 140.13, 139.78, 139.24, 139.17, 136.82, 135.68, 132.36, 131.92, 129.79, 129.13, 100.22, 61.07, 50.20, 20.43, 20.36, 13.93. **HRMS (ESI)** m/z Calcd for $[\text{C}_{20}\text{H}_{21}\text{ClINNaO}_4\text{S}, \text{M} + \text{Na}]^+$: 555.9816; Found: 555.9818.

Optical Rotation: $[\alpha]_D^{25} - 22.0$ ($c = 1.0$, CHCl_3). 91% ee (HPLC condition: Chiralpak AD-H

column, *n*-Hexane/*i*-PrOH = 98:2, flow rate = 1.0 mL/min, wavelength = 254 nm, t_R = 25.17 min for minor isomer, t_R = 27.32 min for major isomer).


Supplementary Figure 63. HPLC Trace of 90a.




9pa. White solid. **MP:** 135-137 °C. **¹H NMR** (500 MHz, CDCl₃) δ 8.37 (d, J = 8.8 Hz, 2H), 8.08 (d, J = 8.8 Hz, 2H), 7.52 (d, J = 1.9 Hz, 1H), 7.06 (d, J = 1.9 Hz, 1H), 6.33 (d, J = 1.2 Hz, 1H), 5.78 (d, J = 1.1 Hz, 1H), 4.68 (d, J = 14.0 Hz, 1H), 4.60 (d, J = 14.0 Hz, 1H), 4.11 (dq, J = 10.9, 7.2 Hz, 1H), 4.04 (dq, J = 10.9, 7.1 Hz, 1H), 2.27 (s, 3H), 2.26 (s, 3H), 1.18 (t, J = 7.1 Hz, 3H). **¹³C NMR** (125 MHz, CDCl₃) δ 165.87, 150.15, 146.73, 142.35, 140.53, 139.25, 136.20, 135.34, 132.53, 132.28, 129.64, 124.12, 99.91, 61.17, 50.54, 20.44, 20.39, 13.96. **HRMS (ESI)** m/z Calcd for [C₂₀H₂₁IN₂NaO₆S, M + Na]⁺: 567.0057; Found: 567.0054.

Optical Rotation: $[\alpha]_D^{25}$ - 17.0 (c = 1.0, CHCl₃). 91% ee (HPLC condition: Chiralpak IC column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, wavelength = 254 nm, t_R = 26.38 min for major isomer, t_R = 44.70 for minor isomer).

Supplementary Figure 64. HPLC Trace of 9pa.







9qa. White solid. **MP:** 142-144 °C. **¹H NMR** (500 MHz, CDCl₃) δ 8.74 (t, *J* = 2.0 Hz, 1H), 8.46 (ddd, *J* = 8.2, 2.2, 1.0 Hz, 1H), 8.21 (dt, *J* = 7.8, 1.4 Hz, 1H), 7.75 (t, *J* = 8.0 Hz, 1H), 7.51 (d, *J* = 2.0 Hz, 1H), 7.07 (d, *J* = 2.1 Hz, 1H), 6.34 (d, *J* = 1.1 Hz, 1H), 5.79 (d, *J* = 1.0 Hz, 1H), 4.67 (d, *J* = 14.1 Hz, 1H), 4.59 (d, *J* = 14.1 Hz, 1H), 4.11 (dt, *J* = 10.8, 7.1 Hz, 1H), 4.02 (dq, *J* = 10.8, 7.1 Hz, 1H), 2.29 (s, 3H), 2.27 (s, 3H), 1.17 (t, *J* = 7.1 Hz, 3H). **¹³C NMR** (125 MHz, CDCl₃) δ 165.86, 148.20, 143.15, 142.33, 140.56, 139.26, 136.33, 135.35, 133.95, 132.57, 132.25, 130.15, 127.21, 123.70, 99.72, 61.15, 50.56, 20.46, 20.40, 13.94. **HRMS (ESI)** *m/z* Calcd for [C₂₀H₂₁IN₂NaO₆S, M + Na]⁺: 567.0057; Found: 567.0060.

Optical Rotation: [α]_D²⁵ - 65.0 (*c* = 1.0, CHCl₃). 93% ee (HPLC condition: Chiralpak IC column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, wavelength = 254 nm, *t*_R = 54.67 min for major isomer, *t*_R = 58.46 for minor isomer).

Supplementary Figure 65. HPLC Trace of **9qa**.



The procedure for the synthesis of **11**, **12** and **13**:





To a dry Schlenk tube equipped with a magnetic stir bar, was added **10ba** (0.1 mmol), Pd(OAc)₂ (0.005 mmol), PPh₃ (0.01 mmol). The tube was closed with a septum, evacuated, and refilled with argon. Dry DMF (0.5 mL) was added and the reaction mixture was then stirred at 25 °C for 10 minutes. After that, HCOOH (0.2 mmol) and Et₃N (0.25 mmol) were added and the mixture was stirred at 60 °C for 10 hours. Upon the reaction completed, the mixture was purified via column chromatography on silica gel to afford the desired product **11**.

Syrup, ¹H NMR (500 MHz, CD₂Cl₂) δ 7.58 (d, *J* = 8.3 Hz, 2H), 7.28 (d, *J* = 8.0 Hz, 2H), 7.00 (d, *J* = 1.7 Hz, 1H), 6.98 (d, *J* = 1.7 Hz, 1H), 4.66 (d, *J* = 12.8 Hz, 1H), 4.01 (qq, *J* = 7.2, 3.7 Hz, 2H), 3.87 (d, *J* = 12.8 Hz, 1H), 2.44 (s, 6H), 2.36 (s, 3H), 1.30 (s, 3H), 1.24 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (125 MHz, CD₂Cl₂) δ 173.45, 143.90, 138.64, 138.38, 136.11, 135.95, 132.13, 129.78, 129.44, 127.48, 122.80, 61.32, 61.06, 51.43, 25.38, 21.30, 20.81, 20.23, 13.79. HRMS (ESI) *m/z* Calcd for [C₂₁H₂₅NNaO₄S, M + Na]⁺: 410.1396; Found: 410.1392.

Optical Rotation: [α]_D²⁵ - 12.0 (*c* = 1.0, CHCl₃). 83% ee (HPLC condition: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 98:2, flow rate = 1.0 mL/min, wavelength = 254 nm, *t*_R = 13.42 min for minor isomer, *t*_R = 15.83 min for major isomer).

Supplementary Figure 66. HPLC Trace of **11**.





To an oven-dried Schlenk tube equipped with a magnetic stir bar was added the **11** (0.05 mmol) and Mg-powder (18.0 mg, 15 equiv.) under Ar atmosphere. Absolute MeOH (1.4 mL) was added and the reaction was capped with a septum, then sonicated at room temperature until full consumption of starting material as monitored by TLC (around 30 min). After cooling to 0 °C, the reaction mixture was slowly quenched with saturated NH₄Cl. The aqueous phases were extracted with DCM (3 × 10 mL). The combined organic phase was washed with saturated brine (20 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexanes/ethyl acetate = 12:1) to afford **12** (81% yield).

Syrup, ¹H NMR (500 MHz, CD₂Cl₂) δ 6.93 (s, 1H), 6.78 (s, 1H), 4.18 (q, *J* = 7.0, 2H), 4.13 (d, *J* = 10.0 Hz, 1H), 3.36 (d, *J* = 10.0 Hz, 1H), 2.26 (s, 3H), 2.13 (s, 3H), 1.54 (s, 3H), 1.29 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (125 MHz, CD₂Cl₂) δ 174.67, 146.79, 131.78, 129.87, 128.35, 121.89, 119.42, 60.97, 57.28, 52.60, 24.34, 20.48, 16.38, 13.92. HRMS (ESI) *m/z* Calcd for [C₁₄H₁₉NNaO₂, M + Na]⁺: 256.1308; Found: 256.1304.

Optical Rotation: [α]_D²⁵ - 18.0 (*c* = 1.0, CH₂Cl₂). 83% ee (HPLC condition: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 95:5, flow rate = 1.0 mL/min, wavelength = 254 nm, *t*_R = 7.89 min for major isomer, *t*_R = 13.39 min for minor isomer).

Supplementary Figure 67. HPLC Trace of **12**.




To a solution of **11** (78 mg, 0.2 mmol) in THF (0.5 mL) were added water (0.5 mL) and LiOH (15 mg, 0.6 mmol). The mixture was allowed to stir at 80 °C overnight. After completion of the reaction (monitored by TLC), the volatiles were evaporated under reduced pressure. The residual aqueous solution was acidified with 3.0 N aqueous HCl solutions (PH < 1.0), and extracted with ethyl acetate. The combined organic layers were dried over Na₂SO₄, filtered and concentrated under

reduced pressure. After recrystallization using diethyl ether, pure acid **13** was obtained as a white solid.

MP: 188-189 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.44 (d, $J = 8.3$ Hz, 2H), 7.09 (d, $J = 8.1$ Hz, 2H), 6.89 (s, 1H), 6.87 (s, 1H), 4.57 (d, $J = 12.9$ Hz, 1H), 3.77 (d, $J = 13.0$ Hz, 1H), 2.37 (s, 3H), 2.24 (s, 3H), 2.23 (s, 3H), 1.23 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 179.50, 143.91, 138.41, 137.66, 136.11, 135.58, 132.66, 130.25, 129.43, 127.74, 122.78, 60.78, 51.29, 25.61, 21.47, 21.05, 20.42. **HRMS (ESI)** m/z Calcd for $[\text{C}_{19}\text{H}_{21}\text{NNaO}_4\text{S}, \text{M} + \text{Na}]^+$: 382.1083; Found: 382.1081.


Optical Rotation: $[\alpha]_D^{25}$ **6.0** ($c = 0.31$, CHCl_3). 96% ee (HPLC condition: Chiralpak AS-H column, n -Hexane/ i -PrOH = 80:20, flow rate = 1.0 mL/min, wavelength = 254 nm, $t_R = 9.14$ min for minor isomer, $t_R = 16.41$ min for major isomer).

Supplementary Figure 68. HPLC Trace of 13.




NMR spectra





Supplementary Figure 69. ¹H and ¹³C NMR Spectra of 1a.




NHMs OH model substrate/1
13C AMX500
Ms



Supplementary Figure 70. ¹H and ¹³C NMR Spectra of 1b.





Supplementary Figure 71. ¹H and ¹³C NMR Spectra of 1c.



Supplementary Figure 72. ¹H and ¹³C NMR Spectra of 1d.



6-Br NHMs OH/1
1H AMX500
6-Br NHMs OH

8.041
8.037
7.820
7.802
7.488
7.468
7.454
7.440
7.436
7.315
7.297
7.019
7.001
5.788
5.439
3.790
2.750
2.430
1.873




6-Br NHMs OH/2
13C AMX500
6-Br NHMs OH

155.048
151.369
133.509
132.941
131.912
131.078
130.844
130.696
130.474
130.176
125.036
123.150
121.550
119.066
117.939
114.519
77.301
77.047
76.793
60.162
39.799
16.590
13.334




Supplementary Figure 73. ¹H and ¹³C NMR Spectra of 1e.

01103 6-CO2Me/3
¹H AMX500
 6-CO2Me





New folder/4
¹³C AMX500
 6-CO2Me





Supplementary Figure 74. ¹H and ¹³C NMR Spectra of 1f.





lsc1031-2/3
1H AMX500
7-Br NHMS OH





lsc1031-2/4
13C AMX500
7-Br NHMS OH





Supplementary Figure 75. ^1H and ^{13}C NMR Spectra of **1g**.



Supplementary Figure 76. ¹H and ¹³C NMR Spectra of 1h.





Supplementary Figure 77. ¹H and ¹³C NMR Spectra of 1i.





Supplementary Figure 78. ¹H and ¹³C NMR Spectra of 1j.

lsc0925/2
1H AMX500
011109 4,6-DiBr bottom





lsc0925/1
13C AMX500
011109 4,6-DiBr bottom





Supplementary Figure 79. ¹H and ¹³C NMR Spectra of 1k.


Nov09-2017\ushc.1.fid
4,6-dime-5-Br sm





Supplementary Figure 80. ¹H and ¹³C NMR Spectra of 11.





Supplementary Figure 81. ^1H and ^{13}C NMR Spectra of **1m**.







Supplementary Figure 82. ^1H and ^{13}C NMR Spectra of **1n**.





Supplementary Figure 83. ^1H and ^{13}C NMR Spectra of **10**.





Supplementary Figure 84. ¹H and ¹³C NMR Spectra of 1p.





Supplementary Figure 85. ^1H and ^{13}C NMR Spectra of **1q**.





Supplementary Figure 86. ¹H and ¹³C NMR Spectra of 3a.




Supplementary Figure 87. ¹H and ¹³C NMR Spectra of 4a.





Supplementary Figure 88. ¹H and ¹³C NMR Spectra of 4b.





Supplementary Figure 89. ^1H and ^{13}C NMR Spectra of **4c**.





Supplementary Figure 90. ^1H and ^{13}C NMR Spectra of 4d.





Supplementary Figure 91. ¹H and ¹³C NMR Spectra of 4e.





Supplementary Figure 92. ^1H and ^{13}C NMR Spectra of **4f**.





Supplementary Figure 93. ¹H and ¹³C NMR Spectra of 4g.





Supplementary Figure 94. ^1H and ^{13}C NMR Spectra of **4h**.





Supplementary Figure 95. ¹H and ¹³C NMR Spectra of 4i.





Supplementary Figure 96. ¹H and ¹³C NMR Spectra of 4j.





Supplementary Figure 97. ¹H and ¹³C NMR Spectra of 4k.





Supplementary Figure 98. ¹H and ¹³C NMR Spectra of 4l.





Supplementary Figure 99. ¹H and ¹³C NMR Spectra of 4m.





Supplementary Figure 100. ^1H and ^{13}C NMR Spectra of 4n.




Supplementary Figure 101. ^1H and ^{13}C NMR Spectra of **40**.




Supplementary Figure 102. ^1H and ^{13}C NMR Spectra of **4p**.







Supplementary Figure 103. ^1H and ^{13}C NMR Spectra of **4q**.





Supplementary Figure 104. ¹H and ¹³C NMR Spectra of 5a.





Supplementary Figure 105. ^1H and ^{13}C NMR Spectra of **5b**.





Supplementary Figure 106. ^1H and ^{13}C NMR Spectra of 6a.





Supplementary Figure 107. ¹H and ¹³C NMR Spectra of 6b.




Supplementary Figure 108. ¹H and ¹³C NMR Spectra of 7.





Supplementary Figure 109. ^1H and ^{13}C NMR Spectra of **8**.




Supplementary Figure 110. ¹H and ¹³C NMR Spectra of 9aa.




Supplementary Figure 111. ¹H and ¹³C NMR Spectra of 9ba.




Supplementary Figure 112. ^1H and ^{13}C NMR Spectra of **9bb**.




Supplementary Figure 113. ^1H and ^{13}C NMR Spectra of **9bc**.




Supplementary Figure 114. ¹H and ¹³C NMR Spectra of 9bd.




Supplementary Figure 115. ^1H and ^{13}C NMR Spectra of **9be**.




Supplementary Figure 116. ^1H and ^{13}C NMR Spectra of **9ca**.



Supplementary Figure 117. ^1H and ^{13}C NMR Spectra of **9da**.





Supplementary Figure 118. ¹H and ¹³C NMR Spectra of 9ea.




Supplementary Figure 119. ^1H and ^{13}C NMR Spectra of **9fa**.


6-ethyl-2,4-diiodide $\text{CHCl}_3/2$
 ^1H AMX500
 131144




Supplementary Figure 120. ¹H and ¹³C NMR Spectra of 9ga.




Supplementary Figure 121. ^1H and ^{13}C NMR Spectra of 9ha.




Supplementary Figure 122. ^1H and ^{13}C NMR Spectra of **9ia**.




Supplementary Figure 123. ¹H and ¹³C NMR Spectra of 9ja.




Supplementary Figure 124. ¹H and ¹³C NMR Spectra of 9ka.




Supplementary Figure 125. ¹H and ¹³C NMR Spectra of 9la.




Supplementary Figure 126. ¹H and ¹³C NMR Spectra of 9ma.




Supplementary Figure 127. ^1H and ^{13}C NMR Spectra of **9na**.




Supplementary Figure 128. ¹H and ¹³C NMR Spectra of 90a.





Supplementary Figure 129. ^1H and ^{13}C NMR Spectra of **9pa**.





Supplementary Figure 130. ¹H and ¹³C NMR Spectra of 9qa.




Supplementary Figure 131. ¹H and ¹³C NMR Spectra of 11.



Supplementary Figure 132. ^1H and ^{13}C NMR Spectra of 12.



Supplementary Figure 133. ^1H and ^{13}C NMR Spectra of 13.



Supplementary References

- [1] J. Chen, Y. Huang, *Org. Lett.* **2017**, *19*, 5609-5612.
- [2] H. Gao, Q.-L. Xu, C. Keene, M. Yousufuddin, D. H. Ess, L. Kürti, *Angew. Chem. Int. Ed.* **2016**, *55*, 566-571.
- [3] H. Gao, D. H. Ess, M. Yousufuddin, L. Kürti, *J. Am. Chem. Soc.* **2013**, *135*, 7086–7089.
- [4] R. A. Singer, J. R. Brock, E. M. Carreira, *Helv. Chim. Acta.* **2003**, *86*, 1040–1044.
- [5] H. Forkosh, V. Vershinin, H. Reiss, D. Pappo, *Org. Lett.*, **2018**, *20*, 2459-2463.
- [6] S. Shirakawa, X. Wu, K. Maruoka, *Angew. Chem. Int. Ed.* **2013**, *52*, 14200–14203
- [7] H. Liu, S. Liu, H. Zhou, Q. Liu, C. Wang, *RSC Adv.*, **2018**, *8*, 14829-14832.